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A B S T R A C T
Background
Chronic obstructive pulmonary disease (COPD) is a respiratory condition causing accumulation of mucus in the airways, cough, and
breathlessness; the disease is progressive and is the fourth most common cause of death worldwide. Current treatment strategies for
COPD are multi-modal and aim to reduce morbidity and mortality and increase patients’ quality of life by slowing disease progression
and preventing exacerbations. Fixed-dose combinations (FDCs) of a long-acting beta2-agonist (LABA) plus a long-acting muscarinic
antagonist (LAMA) delivered via a single inhaler are approved by regulatory authorities in the USA, Europe, and Japan for the treatment
of COPD. Several LABA/LAMA FDCs are available and recent meta-analyses have clarified their utility versus their mono-components
in COPD. Evaluation of the efficacy and safety of once-daily LABA/LAMA FDCs versus placebo will facilitate the comparison of
different FDCs in future network meta-analyses.
Objectives
Weassessed the evidence for once-daily LABA/LAMAcombinations (delivered in a single inhaler) versus placeboon clinicallymeaningful
outcomes in patients with stable COPD.
Search methods
We identified trials from Cochrane Airways’ Specialised Register (CASR) and also conducted a search of the US National Institutes of
Health Ongoing Trials Register ClinicalTrials.gov ( www.clinicaltrials.gov) and the World Health Organization International Clinical
Trials Registry Platform ( apps.who.int/trialsearch). We searched CASR and trial registries from their inception to 3 December 2018;
we imposed no restriction on language of publication.
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Selection criteria
We included parallel-group and cross-over randomised controlled trials (RCTs) comparing once-daily LABA/LAMA FDC versus
placebo. We included studies reported as full-text, those published as abstract only, and unpublished data. We excluded very short-term
trials with a duration of less than 3 weeks. We included adults (≥ 40 years old) with a diagnosis of stable COPD. We included studies
that allowed participants to continue using their ICS during the trial as long as the ICS was not part of the randomised treatment.
Data collection and analysis
Two review authors independently screened the search results to determine included studies, extracted data on prespecified outcomes
of interest, and assessed the risk of bias of included studies; we resolved disagreements by discussion with a third review author.
Where possible, we used a random-effects model to meta-analyse extracted data. We rated all outcomes using the GRADE (Grades of
Recommendation, Assessment, Development and Evaluation) system and presented results in ’Summary of findings’ tables.
Main results
We identified and included 22 RCTs randomly assigning 8641 people with COPD to either once-daily LABA/LAMA FDC (6252
participants) or placebo (3819 participants); nine studies had a cross-over design. Studies had a duration of between three and 52 weeks
(median 12 weeks). The mean age of participants across the included studies ranged from 59 to 65 years and in 21 of 22 studies,
participants had GOLD stage II or III COPD. Concomitant inhaled corticosteroid (ICS) use was permitted in all of the included
studies (where stated); across the included studies, between 28% to 58% of participants were using ICS at baseline. Six studies evaluated
the once-daily combination of IND/GLY (110/50 µg), seven studies evaluated TIO/OLO (2.5/5 or 5/5 µg), eight studies evaluated
UMEC/VI (62.5/5, 125/25 or 500/25 µg) and one study evaluated ACD/FOR (200/6, 200/12 or 200/18 µg); all LABA/LAMA
combinations were compared with placebo.
The risk of bias was generally considered to be low or unknown (insufficient detail provided), with only one study per domain considered
to have a high risk of bias except for the domain ’other bias’ which was determined to be at high risk of bias in four studies (in three
studies, disease severity was greater at baseline in participants receiving LABA/LAMA compared with participants receiving placebo,
which would be expected to shift the treatment effect in favour of placebo).
Compared to the placebo, the pooled results for the primary outcomes for the once-daily LABA/LAMA arm were as follows: all-cause
mortality, OR 1.88 (95% CI 0.81 to 4.36, low-certainty evidence); all-cause serious adverse events (SAEs), OR 1.06 (95% CI 0.88
to 1.28, high-certainty evidence); acute exacerbations of COPD (AECOPD), OR 0.53 (95% CI 0.36 to 0.78, moderate-certainty
evidence); adjusted St George’s Respiratory Questionnaire (SGRQ) score, MD -4.08 (95% CI -4.80 to -3.36, high-certainty evidence);
proportion of SGRQ responders, OR 1.75 (95% CI 1.54 to 1.99). Compared with placebo, the pooled results for the secondary
outcomes for the once-daily LABA/LAMA arm were as follows: adjusted trough forced expiratory volume in one second (FEV1), MD
0.20 L (95% CI 0.19 to 0.21, moderate-certainty evidence); adjusted peak FEV1, MD 0.31 L (95% CI 0.29 to 0.32, moderate-
certainty evidence); and all-cause AEs, OR 0.95 (95% CI 0.86 to 1.04; high-certainty evidence). No studies reported data for the 6-
minute walk test. The results were generally consistent across subgroups for different LABA/LAMA combinations and doses.
Authors’ conclusions
Compared with placebo, once-daily LABA/LAMA (either IND/GLY, UMEC/VI or TIO/OLO) via a combination inhaler is associated
with a clinically significant improvement in lung function and health-related quality of life in patients with mild-to-moderate COPD;
UMEC/VI appears to reduce the rate of exacerbations in this population. These conclusions are supported bymoderate or high certainty
evidence based on studies with an observation period of up to one year.
P L A I N L A N G U A G E S U M M A R Y
Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for COPD
We wanted to know whether once-daily treatment with a fixed-dose combination of a long-acting beta2 agonist (LABA) plus a long-
acting muscarinic antagonist (LAMA) delivered via a single inhaler is better than treatment with a dummy inhaler (placebo) for people
with chronic obstructive pulmonary disease (COPD).
Background to the review
2Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic
obstructive pulmonary disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
COPD is a disease of the lungs and is the fourth most common cause of death worldwide. People with COPD experience symptoms
of cough, breathlessness and a build up of mucus, which become worse over time. Current treatments for COPD aim to manage these
symptoms and improve the quality of life of people with the disease.
A combination of a LABA plus a LAMA taken once-daily in a single inhaler (LABA/LAMA) has been shown to be more effective than
taking each separately in individual inhalers. Several different combinations of inhaled LABA and LAMA are available (e.g. indacaterol/
glycopyrronium, olodaterol/tiotropium, formoterol/aclidinium, and vilanterol/umeclidinium) and are used for the treatment of COPD.
By gathering information from clinical trials that compare once-daily LABA/LAMA with placebo in a dummy inhaler we will provide
information to help future research decide which combination is best for treating people with COPD.
What did we find?
Twenty-two studies (including 8641 people with COPD) compared once-daily LABA/LAMA in a single inhaler with a dummy inhaler.
People were allowed to continue to use their inhaled corticosteroids (ICS) during the studies; approximately a third to a half of people
were using their ICS at the beginning of each study. The evidence presented in this review is current up to December 2018. The
majority of people who took part in the studies had mild-to-moderate COPD and the average age of people in each study ranged from
59 to 65 years. Six studies evaluated the once-daily combination of indacaterol/glycopyrronium, seven studies evaluated tiotropium/
olodaterol, eight studies evaluated umeclidinium/vilanterol and one study evaluated aclidinium/formoterol.
People who took once-daily LABA/LAMA using a single inhaler showed a greater improvement in quality of life than those taking
placebo in a dummy inhaler; lung function was also improved in people taking once-daily LABA/LAMA. People taking umeclidinium/
vilanterol had fewer flare-ups (exacerbations). There was no significant difference between groups (LABA/LAMA versus placebo) in
the number of people who died, or in the number of people who experienced serious adverse events or any adverse event. The results
were similar for the different LABA/LAMA combinations and doses that we evaluated.
The included studies were generally well designed and well reported. People in the studies and those performing the research did not
know which treatment people were receiving, which ensures a fair evaluation of the treatments.
In three of the studies, people who were taking once-daily LABA/LAMA had more severe COPD at the start of the study than people
taking dummy inhalers; this could have reduced the treatment effect seen with LABA/LAMA in these studies so we can be confident
that our findings do not overestimate the effect seen with once-daily LABA/LAMA. One of the outcomes of interest (how far a person
is able to walk in six minutes) was not reported by any of the included studies. Overall, we can be confident in the conclusions of this
review.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Once daily LABA/LAMA in a combined inhaler compared with placebo in adults with COPD
Patient or population: Adults with COPD
Setting: Clinical pract ice (primary care/ secondary care/ academic centres)
Intervention: Once-daily LABA/ LAMA in a combined inhaler
Comparison: Placebo
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(HRQoL)
Scale 0-100, lower on
the scale is better.
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with placebo ranged
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Dif ference vs placebo
in adjusted trough FEV1
at EOT
(3-week to 1-year fol-
low-up)
Mean change f rom
baseline in trough FEV1
with placebo ranged
f rom 0.08 L lower to 0.
01 L higher
MD 0.20 L higher







Dif ference vs placebo
in adjusted peak FEV1
(3-week to 6-month fol-
low-up)
Mean change f rom
baseline in peak FEV1
with placebo ranged
f rom 0.04 to 0.1 L
higher
MD 0.31 L higher
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
COPD: chronic obstruct ive pulmonary disease; CI: conf idence interval; EOT : end of treatment; FEV1: f orced expiratory volume in 1 second; HRQoL: health-related quality of
lif e; LABA: long-act ing beta-adrenoceptor agonist ; LAMA: long-act ing muscarinic antagonist ; MCID: minimum clinically important dif f erence; MD: mean dif ference; OR: odds
rat io; RR: risk rat io; SGRQ: St George’s Respiratory Quest ionnaire; UMEC: umeclidinium; VI: vilanterol.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded once for indirectness; durat ion of treatment varied widely: maximum durat ion 52 weeks, n = 3 studies durat ion
< 6 weeks.
2 Downgraded once for imprecision; wide 95% conf idence intervals due to low number of events - conf idence intervals
encompassed no ef fect, benef it , and risk.
3 Downgraded once for indirectness as all studies examined UMEC/ VI.
4 Downgraded once for inconsistency; signif icant heterogeneity (overall I2 ≥ 68%), not ing that ef fect sizes were sim ilar




























































































































































B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is a progressive
condition resulting from the complex interplay between environ-
mental exposures (e.g. cigarette smoke) and genetic factors (Barnes
2015). The disease is characterised by a chronic limitation of air-
flow, which is not fully reversible, and intermittent exacerbations
during which symptoms increase in severity. Symptoms include
shortness of breath, increased sputum production and cough. The
condition is diagnosed objectively by spirometric evaluation, with
a post bronchodilator forced expiratory volume in one second/
forced vital capacity (FEV1/FVC) < 0.70 confirming the pres-
ence of airflow limitation. COPD severity is graded by the extent
of airflow limitation according to international guideline criteria
(GOLD 2017).
COPD is the fourth most common cause of death worldwide
(WHO 2015), and has an estimated prevalence of 6.4%; the bur-
den on worldwide healthcare services is significant (CDC 2016;
GOLD 2017).
Current treatment strategies are multi-modal and aim to reduce
morbidity and mortality and increase patients’ quality of life by
slowing disease progression and preventing exacerbations. Inter-
ventions include cessation of smoking and pulmonary rehabilita-
tion, vaccination against influenza and pneumonia, and the use of
inhaled corticosteroids (ICS) and bronchodilators (GOLD 2017).
Supplemental oxygen is a life-prolonging option in hypoxaemic
patients. Although treatment is not curative, patients may occa-
sionally be candidates for lung transplantation (GOLD 2017).
Description of the intervention
Long-acting beta2-agonists (LABA) and long-acting anticholiner-
gics (LAMA) are commonly used in patients with COPD as rec-
ommended by COPD guidelines (GOLD 2017;Wedzicha 2017).
Each bronchodilator can be taken individually or in combination
using either two separate inhalers or a single inhaler in a fixed-
dose combination (FDC; denoted herein by LABA/LAMA). Ev-
idence suggests that combination of a LABA and tiotropium in
individual inhalers offers benefits over the use of either component
alone, in terms of lung function and quality of life (Farne 2015).
The need for single-inhaler fixed-dose combinations arose for sev-
eral reasons including the underwhelming efficacy of salmeterol
and tiotropium administered via separate devices (Aaron 2007)
and potential advantages in terms of convenience and adherence
(Bangalore 2007). This review has synthesised the evidence for
the safety and efficacy of once-daily LABA/LAMA FDCs versus
placebo in patients with COPD.
How the intervention might work
The co-administration of LABA/LAMA in COPD has beneficial
effects on lung function, dyspnoea scores, health-related quality
of life, and possibly in preventing acute exacerbations of COPD
(AECOPD) (Calzetta 2016; Wedzicha 2014). Bronchodilation is
thought to form the foundation of these benefits, but a reduction
in hyperinflation, modulation of mucous production and clear-
ance, and potentially anti-inflammatory effects are theorised to
contribute as well (Beeh 2016). In terms of bronchodilation, use
of LABA and LAMA together is more effective compared to either
agent alone (Singh 2014a; Van Noord 2005), but the nature of
this interaction is not entirely clear, with in vitro and clinical stud-
ies suggesting that there is a synergistic rather than additive effect
(Cazzola 2015). The mechanism of increased bronchodilation has
mainly been attributed to the activation of presynaptic beta2-re-
ceptors, which attenuates the release of junctional acetylcholine
(Calzetta 2015). In addition, airway smooth muscle relaxation
achieved by a LABA (via increased cyclic adenosine monophos-
phate) is amplified by the blockade of acetylcholine by inhibition
of M3 muscarinic receptors (Cazzola 2010), and there is evidence
to suggest that M2 receptors interact with adenyl cyclase as well
(Beeh 2016).
Why it is important to do this review
Fixed-dose combinations (FDCs) of a long-acting beta2-agonist
(LABA) plus a long-acting muscarinic antagonist (LAMA) de-
livered via a single inhaler are approved by regulatory authori-
ties in the USA, Europe, and Japan for the treatment of COPD
. The introduction of these inhalers follow guideline-based rec-
ommendations to optimise inhaled bronchodilator use (Quaseem
2011; Vestbo 2013). Recentmeta-analyses have clarified the utility
of LABA/LAMA combination inhalers compared to their mono-
components in COPD, particularly with respect to trough FEV1,
transitional dyspnoea index (TDI), St. George’s Respiratory Ques-
tionnaire (SGRQ) and safety (Calzetta 2016; Calzetta 2017).
They found statistically and clinically significant improvements
in trough FEV1 for all fixed-dose combinations (FDC) com-
pared with their mono-components. Though there were statis-
tically significant improvements in TDI and SGRQ, these fell
below previously established minimal clinically important differ-
ences (MCIDs), and thus the clinical meaning of this benefit is un-
clear. Side effects, including cardiac events, were no greater in those
taking LABA/LAMA. There were no significant differences be-
tween different FDCs for the outcomes examined (Calzetta 2016;
Calzetta 2017). Individual clinical trials have demonstrated a re-
duction in AECOPD with LABA/LAMA versus mono-compo-
nents and versus placebo (Bateman 2015; Wedzicha 2017). Un-
fortunately, the benefits of LABA/LAMA on AECOPD were not
included in the meta-analyses, and thus remain to be clarified.
Evaluation of the efficacy and safety of once-daily LABA/LAMA
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fixed-dose combinations versus placebo will facilitate the compar-
ison of different FDCs in future network meta-analyses.
O B J E C T I V E S
To assess the effects of single-inhaler LABA/LAMA combinations
versus placebo on clinically meaningful outcomes in patients with
stable COPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel-group and cross-over randomised controlled
trials (RCTs). We included studies reported as full-text, those pub-
lished as abstract only, and unpublished data. We excluded very
short-term trials (i.e. ≤ three weeks in duration).
Types of participants
We included adults (≥ 40 years old) with a diagnosis of stable
COPD. We recorded study authors’ definition of stable COPD.
We did not exclude participants with comorbidities.
Types of interventions
We included trials comparing once-daily LABA/LAMA in a single
inhaler (i.e. fixed dose combination) versus placebo.
We included studies that allowed participants to continue using
their ICS during the trial as long as the ICS was not part of the
randomised treatment; if ICS was administered in combination
with LABA prior to the trial, participants should be transitioned
to the equivalent ICS monotherapy prior to study start. The effect
of continued ICS use was planned to be examined by subgroup
analysis (see Subgroup analysis and investigation of heterogeneity).
Types of outcome measures
Primary outcomes
1. All-cause mortality.
2. Serious Adverse Events (SAE) of any cause.
3. Acute Exacerbations of COPD (AECOPD).
4. Respiratory Health-related Quality of Life (HRQoL), as
measured by the
i) St. George’s Respiratory Questionnaire (SGRQ).
ii) Chronic Respiratory Questionnaire (CRQ).
Comments about primary outcomes
Serious adverse events
SAEs can include death, life-threatening adverse reaction, hospi-
talisation or increased length of hospital stay, disability, and birth
defects. We recorded each study’s definition of an SAE if it varied
from our definition.
Respiratory health-related quality of life
CRQ and SGRQ are widely-used, reliable and valid measures of
patient-reported health status in COPD (Guyatt 1987; Jones
1992). SGRQ scores three domains of health status (symptoms,
patient activity, and disease impact), and reports scores ranging
from zero (best) to 100 (worst). TheMinimally Clinical Important
Difference (MCID) is approximately four (Schunemann 2003).
That is, a clinically meaningful change in health status is equal
to a change of about four points on SGRQ. CRQ scores four
domains (shortness of breath, fatigue, emotional function, and
mastery), reports scores ranging from one (worst) to seven (best),
and has an MCID of 0.5 (Schunemann 2005). While CRQ and
SGRQ provide very similar information and are highly correlated,
SGRQ is less responsive; it was shown to underestimate treatment
effects when compared to CRQ in identical populations (Puhan
2006). Thus, pooling SGRQ data with CRQ data may spuriously
suggest heterogeneity of treatment effect. Therefore, SGRQ and
CRQ were considered as separate outcomes; this approach agrees
with the recommendations of Puhan 2006, who suggest that mean
differences for SGRQ and CRQ should be reported separately.
Acute exacerbations of COPD
We included AECOPD as a main outcome because exacerbations
are consistently linked to mortality, morbidity, and costly hospi-
talisations. Since a consensus definition and standard reporting
criteria do not exist for AECOPD (Cazzola 2008), we performed a
meta-analysis of AECOPDdata only when study authors used one
of the following definitions: increase in symptoms precipitating
the use of antibiotics; increase in symptoms precipitating the use of
systemic steroids; increase in symptoms precipitating emergency
room visit; or hospitalisation. TheMCID for AECOPDoutcomes
is not established: Calverley 2005 estimated an MCID of 20% to
25% using a crude anchor-based approach, while Chapman 2013
used an expert consensus process to estimate an MCID of 11%.
Secondary outcomes
1. Trough (pre-dose) Forced Expiratory Volume in One
Second (FEV1).
2. Peak (post-dose) FEV1.
3. Six-minute walking test (6MWT).
4. Adverse effects.
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Comments about secondary outcomes
Forced expiratory volume
FEV1 is the volume of air forcibly exhaled one second after maxi-
mum inhalation. FEV1 is often used for staging COPD (GOLD
2017): FEV1 is 20% lower than normal for patients with mild
COPD and 70% lower than normal for patients with very severe
COPD. FEV1 is also used to assess treatment effect. However,
the MCID for FEV1 has not been quantitatively established (ex-
pert opinion proposes an MCID of 100 mL to 140 mL) (Cazzola
2008). Moreover, FEV1 is an intermediate endpoint, representing
airflow as a surrogate for clinically important outcomes. Surro-
gate outcomes are not patient-centred. Nevertheless, we included
trough FEV1 because one meta-analysis points to a modest cor-
relation between increased trough FEV1 and improved SGRQ
(Westwood 2011). For the purpose of this review we will consider
the MCID for FEV1 to be 100 mL (Donohue 2005).
Six-minute walking test
In the ECLIPSE study (a non-interventional cohort study of
treated COPD patients), one-year change in 6MWT predicted
death in the subsequent 12 months. The mean between-group
change between survivors and non-survivors was 30 metres (95%
CI 26 to 34). Using these results, Polkey 2013 proposed anMCID
of about 30 metres.
Adverse effects
We analysed all-cause adverse effects and serious adverse events
reported in studies of LABA or LAMA.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Airways Trials Register on 3 December
2018. The Cochrane Airways Trials Register is maintained by the
Information Specialist for the Group and contains studies identi-
fied from several sources:
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies - CRS Web;
2. Weekly searches of MEDLINE Ovid SP;
3. Weekly searches of Embase Ovid SP;
4. Monthly searches of PsycINFO Ovid SP;
5. Monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature);
6. Monthly searches of AMED EBSCO (Allied and
Complementary Medicine);
7. Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register were identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference
proceedings, are in Appendix 1. See Appendix 2 for search terms
used to identify studies for this review.
We searched the following trials registries on 3 December 2018:
1. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov);
2. World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch).
We searched the Cochrane Airways Trials Register and additional
sources from inception, with no restriction on language of publi-
cation.
Searching other resources
We checked reference lists of all primary studies and review articles
for additional references.We searched relevantmanufacturers’ web
sites for trial information.
We searched for errata or retractions from included studies pub-
lished in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and reported the date this was done within the review.
Data collection and analysis
Selection of studies
Two review authors (DE, UM, RW, or TH) independently
screened each title and abstract for inclusion of all the potential
studies we identified as a result of the search and coded them
as ’retrieve’ (eligible or potentially eligible/unclear) or ’do not re-
trieve’. We retrieved the full-text study reports/publications that
appeared eligible and two review authors (DE, UM, TH, or RW)
independently screened each full-text paper and identified stud-
ies for inclusion, or identified and recorded reasons for exclusion
of the ineligible studies. We resolved any disagreement through
discussion or, if required, we consulted a third person (DE, UM,
RW, or TH). We identified and excluded duplicates and collated
multiple reports of the same study so that each study rather than
each report was the unit of interest in the review. We recorded the
selection process in sufficient detail to complete a PRISMA flow
diagram and Characteristics of excluded studies table.
Data extraction and management
We used a data collection form for study characteristics and out-
come data which had been piloted on at least one study in the re-
view. Two review authors (DE, UM, RW, or TH) extracted study
characteristics from each included study. We extracted the follow-
ing study characteristics.
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1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (DE, UM, RW, or TH) independently ex-
tracted outcome data from each included study. We noted in the
Characteristics of included studies table if outcome data were not
reported in a usable way. We resolved disagreements by consensus
or by involving a third person (DE, UM, RW, or TH). One re-
view author (DE) transferred data into the Review Manager file.
We double-checked that data have been entered correctly by com-
paring the data presented in the systematic review with the study
reports. A second review author (RW) spot-checked study charac-
teristics for accuracy against the trial report.
Trials may report continuous outcomes as change scores (i.e.
change from baseline) or final values. As per the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011), we pre-
sented mean differences in change scores in one subgroup, mean
differences in final values in another, and pooled both subgroups
for an overall analysis.
Where multiple time points were reported for outcomes, we chose
the time point that maximised length of follow-up for the ran-
domised treatment period.
Assessment of risk of bias in included studies
Two review authors (DE, KP, or FE) independently assessed the
risk of bias for each study using the criteria outlined in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreements by discussion or by involving a
third author (DE, KP, or FE).We assessed the risk of bias according
to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear
and provided a quote from the study report together with a jus-
tification for our judgement in the ’Risk of bias’ table. We sum-
marised the risk of bias judgements across different studies for
each of the domains listed. We considered blinding separately for
different key outcomes, where necessary (e.g. for unblinded out-
come assessment, risk of bias for all-cause mortality may be very
different than for a patient-reported pain scale). Where informa-
tion on risk of bias related to unpublished data or correspondence
with a trialist, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to this published protocol
and reported any deviations from it in the Differences between
protocol and review section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as odds ratios and continuous data
as mean differences or standardised mean differences. We entered
data presented as a scale with a consistent direction of effect.
We performed meta-analyses only where this was meaningful, i.e.
if the treatments, participants, and the underlying clinical question
were similar enough for pooling to make sense.
We narratively described skewed data reported as medians and
interquartile ranges.
Where multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) were combined in the
same meta-analysis, we halved the control group to avoid double-
counting.
Unit of analysis issues
We analysed dichotomous data using participants as the unit of
analysis (rather than events) to avoid counting the same participant
more than once. Paired data from each participant in cross-over
trials were analysed using the Generic Inverse Variance method.
Dealing with missing data
We contacted investigators or study sponsors in order to obtain
missing numerical outcome data where possible (e.g. when a study
was identified as abstract only). That is, if study authors did not
report true intention-to-treat (ITT) data, we attempted an avail-
able case analysis by including data for all participants for whom
outcome data were collected (whether the participants completed
or did not complete the trial). Please note that a case analysis is
not a true ITT analysis, nor a per-protocol analysis.
If we could not obtainmissingdata from study authors, we planned
to:
1. compare our available case analysis with an imputed, true
ITT analysis (see Sensitivity Analyses);
2. use an average standard deviation (SD) borrowed from
other studies included in our meta-analysis if the SD for a mean
difference was unavailable (or incalculable);
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3. use final values instead of the change-from-baseline values if
the standard deviation for a change score was missing.
If the missing data were thought to introduce serious bias, we
planned to explore the impact of including such studies in the
overall assessment of results by a sensitivity analysis.
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials
in each analysis. If we identified substantial heterogeneity (i.e. I2
greater than 30%) we reported it and explored possible causes by
prespecified subgroup analysis.
Assessment of reporting biases
If we were able to pool more than 10 trials, we planned to create
and examine a funnel plot to explore possible small study and
publication biases.
Data synthesis
We used a fixed-effect model and performed a sensitivity analysis
with a random-effects model. Where study authors reported ex-
acerbation rate, we meta-analysed rate data when study authors
accounted for duration of follow-up and inter-patient variability
(Aaron 2008). The odds ratio was our primary summary statis-
tic. Where possible, we also reported AECOPD as the percentage
of participants experiencing at least one exacerbation. This way,
AECOPD could be presented as a dichotomous outcome, and a
patient-based number needed to treat for an additional beneficial
outcome (NNTB) could be reported. When possible, we also re-
ported SGRQ and CRQ as dichotomous outcomes (i.e. partici-
pants who reached the MCID versus participants who did not).
Summary of findings table
We created a ’Summary of findings’ table using the seven primary
and secondary outcomes identified above; for health-related qual-
ity of life, SGRQ was reported in the ’summary of findings’ table.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness, and publication bias)
to assess the certainty of a body of evidence as it related to the
studies which contributed data to the meta-analyses for the pre-
specified outcomes. We used the methods and recommendations
described in Section 8.5 and Chapter 12 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) using
GRADEpro software. We justified all decisions to downgrade or
upgrade the certainty of the evidence using footnotes and wemade
comments to aid reader’s understanding of the review, where nec-
essary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses:
1. participants with ICS use during the trial versus
participants without ICS use during the trial;
2. different LABA/LAMA combinations (IND/GLY; UMEC/
VI; TIO/OLO; ACM/FOR);
3. length of follow-up (less than six months versus six months
or longer);
4. baseline COPD severity (mild or moderate disease versus
severe disease, according to GOLD criteria).
We used our primary outcomes in subgroup analyses.
We used the formal test for subgroup interactions in ReviewMan-
ager.
Sensitivity analysis
We planned to carry out the following sensitivity analyses:
1. a comparison of available case analysis to true ITT analyses,
where the ITT analyses were imputed with best-case and worse-
case outcome data;
2. a comparison of results from fixed-effect models with
results from random-effects models;
3. a comparison based on our ’risk of bias’ assessments (i.e.
exclusion of studies with a high risk of bias).
R E S U L T S
Description of studies
The Characteristics of included studies tables presents details of
the included studies; a summary table is also provided (Table 1). In
the Characteristics of excluded studies table, we reported reasons
for the exclusion of studies considered during review of full-text
articles.
Results of the search
We identified 1114 records by performing electronic searches of
bibliographic databases . Of a total of 1059 records (55 duplicates
removed), we excluded 765 upon screening titles and abstracts.
We examined full-text articles of the remaining 294 records and
excluded 220 records (reporting 96 studies; see Excluded studies).
The remaining 74 records reported the findings of 23 studies,
which we included in this review (studies included in quantitative
analyses, n = 22; studies awaiting classification, n = 1). Figure 1
depicts the flow of information through the different stages of this
systematic review.
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Figure 1. Study flow diagram.
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Included studies
Of the 23 studies thatmet the inclusion criteria, there were twenty-
two included studies (Bateman 2013; Beeh 2014; Beeh 2015;
Celli 2014; Dahl 2013; Donohue 2013; Feldman 2012; Larbig
2015;Mahler 2014;Maltais 2014b;Maltais 2014c; Maltais 2014;
NCT00626522; NCT02275052; O’Donnell 2015a; O’Donnell
2015b; Siler 2016; Singh 2016a; Singh 2016b; Troosters 2016;
Watz 2016; Zheng 2014) and one study awaiting classification
(NCT02233543 2014). A majority of included studies were re-
ported as full peer-reviewed articles, with the exception of those
reported as abstract only (Larbig 2015) or trial registry only
(NCT00626522 and NCT02275052).
Methods
Of the included studies, 13 had a parallel-group design and nine
had a cross-over design; all 22 studies were described as double-
blind (blinding of participants and staff occurred in 15 studies
and was unclear in seven studies; blinding of outcome assessors
occurred in six studies and was unclear in 16 studies). Studies had
a randomly assigned treatment period ranging from three weeks
to 52 weeks (mean 11 weeks; median 12 weeks; mode 12 weeks);
a minority of studies had a duration of six months or longer (6
months, n = 4; 12 months, n = 2). All studies were multicentre
studies; 19 of 22 studies were international, with the exception
of trials performed solely in Germany (Watz 2016) or the USA
(Feldman 2012; NCT02275052). Overall, there was good geo-
graphical coverage; themajority of studies (16/22) enrolled partic-
ipants from both Europe and North America and studies also en-
rolled a proportion of participants fromChina and Asia (Bateman
2013;Dahl 2013;Donohue 2013; Larbig 2015; Siler 2016),Ocea-
nia (O’Donnell 2015a; O’Donnell 2015b; Singh 2016a; Singh
2016b; Troosters 2016), Russia (Maltais 2014c; NCT00626522;
O’Donnell 2015a; O’Donnell 2015b; Siler 2016) and South
Africa (Dahl 2013; Maltais 2014b; Singh 2016a; Singh 2016b).
Study setting was poorly reported, but appeared to represent a mix
of academic/clinical research centres and primary or secondary
care units.
Participants
The twenty-two included studies randomised a total of 8641 par-
ticipants (Table 1). Baseline characteristics were generally consis-
tent across studies. Inclusion criteria for the majority of studies (n
= 21/22) specified either GOLD stage II/III, or criteria aligned
with this disease severity (i.e. post-bronchodilator FEV1 < 70%
or 80%; post-bronchodilator FVC/FEV1 < 70%; MRC dyspnoea
score ≥ 2); Beeh 2015 permitted inclusion of participants with
GOLD stage II to IV. The mean ages of participants across the
relevant arms of all included studies ranged from 59 to 65 years;
the proportion of current smokers generally ranged from 40% to
55% (n = 20; two outliers: 25% (Zheng 2014) and 78% (Feldman
2012)). In each trial, a majority of participants were male (range
across studies 53% to 82%; one outlier, 92% to 94% (Zheng
2014)). Where reported, post-bronchodilator percent predicted
FEV1 ranged from 47% to 62% (median ~58%); Zheng 2014 did
not report % predicted FEV1, but pre-bronchodilator FEV1 was
1.2 L to 1.3 L; Larbig 2015, NCT00626522, NCT02275052 and
Troosters 2016 did not report baseline lung-function (abstract or
trial registry only). Concomitant inhaled corticosteroid (ICS) use
was permitted in all of the included studies (where stated); across
the included studies, between 28% to 58% of participants were
using ICS at baseline.
Intervention
Of the 8641 randomised participants across the 22 studies, and
accounting for the enrolment in multiple arms of cross-over stud-
ies, a total of 6252 participants were randomised to receive once-
daily LABA/LAMA via a combined inhaler, and 3819 participants
were randomised to receive placebo. In the subgroup of parallel-
group trials, 4124 participants were randomised to receive once-
daily LABA/LAMA via a combined inhaler and 2520 participants
were randomised to receive placebo. Across the 22 studies, six
studies evaluated the once-daily combination of IND/GLY (110/
50 µg), seven studies evaluated TIO/OLO (2.5/5 or 5/5 µg),
eight studies evaluated UMEC/VI (62.5/5, 125/25 or 500/25 µg)
and one study evaluated ACD/FOR (200/6, 200/12 or 200/18
µg); all LABA/LAMA combinations were compared with placebo.
Where reported, concomitant treatment with ICS was permitted
by all studies with various restrictions relating to prior use and sta-
ble dose for a prespecified time prior to study initiation; whether
concomitant ICS was permitted was not reported for one study
(Troosters 2016).
Outcomes
With the exception of the 6MWT (secondary outcome), all of
the prespecified outcomes were reported by at least three of the
included studies. All-cause mortality was reported by 18 studies,
SAEs, by all 22 studies, AECOPD by three studies, difference
versus placebo in adjusted trough FEV1 by 13 studies, difference
versus placebo in adjusted peak FEV1 by seven studies, differ-
ence versus placebo in adjusted SGRQ score by eight studies, and
all-cause AEs by 18 studies (Summary of findings for the main
comparison). 6MWT was not reported by any of the included
studies.
12Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic
obstructive pulmonary disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Excluded studies
Ninety-six studies were excluded, primarily because either the in-
tervention did not meet the inclusion criteria (i.e. the LAMA and
LABA were not administered once-daily in a fixed dose combi-
nation, or the combination was administered twice daily; n = 36
studies) or because the study did not include a placebo arm (n =
38). It was often difficult to ascertain from the abstract whether
the LAMA and LABA were administered as a fixed-dose combi-
nation and from the clinical trial record headers it was not always
possible to identify whether a placebo group was included; this
resulted in a high rate of exclusions at full-text review stage. Other
reasons for exclusion at this stage included ’duration < 3 weeks’ (n
= 21), ’wrong participant population’ (healthy volunteers; n = 1).
Risk of bias in included studies
Please refer to the Characteristics of included studies tables for
details on risk of bias and for supporting evidence for each study.
Figure 2 provides a summary of ’risk of bias’ judgements, presented
by study and domain (sequence generation, allocation conceal-
ment, blinding, incomplete data, selective reporting and ’other’).
Figure 3 depicts the risk of bias for each domain, presented as per-
centages across all included studies. Across 198 assessments (22
studies, nine risk of bias domains), 146 were considered to be at
a low risk of bias, seven at a high risk of bias and 45 to have an
unclear risk of bias.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
More than half of the included studies provided insufficient in-
formation regarding methods of random sequence generation (11
of 22 studies) and concealment of treatment allocation (12 of
22 studies) to allow a judgement on risk of bias; the risk of bias
for these studies was rated as unclear. Ten studies employed ad-
equate methods of random sequence generation and were con-
sidered to be at low risk of bias. (Bateman 2013; Beeh 2014;
Donohue 2013; Feldman 2012; Mahler 2014; Maltais 2014b;
Maltais 2014c; Siler 2016; Watz 2016; Zheng 2014) or adequate
methods of allocation concealment (Bateman 2013; Beeh 2014;
Donohue 2013; Feldman 2012; Mahler 2014; Maltais 2014b;
Maltais 2014c; Siler 2016; Troosters 2016; Zheng 2014). Inade-
quate methods of random sequence generation (pseudo-random
number generator and block randomisation) were employed in
one study (Troosters 2016), which was considered to be at high
risk of bias.
Blinding
We considered the risk of performance and detection bias sepa-
rately for objective and subjective outcomes. For objective out-
comes (all-cause mortality, SAEs, AECOPD, lung function and
AEs) we considered that a lack of blinding would not result in a
risk of detection or performance bias; therefore all studies were
considered to be at low risk of bias with respect to these out-
comes. The only subjective outcome relevant to this review was
HRQoL based on assessment by SGRQ; sixteen studies were con-
sidered to be at a low risk of performance bias (Bateman 2013;
Beeh 2014; Celli 2014; Dahl 2013; Donohue 2013; Feldman
2012; Larbig 2015; Mahler 2014; Maltais 2014b; Maltais 2014c;
NCT00626522; NCT02275052; Siler 2016; Troosters 2016;
Watz 2016; Zheng 2014); and the risk of performance bias was
unclear for the remaining six studies (Beeh 2015; Maltais 2014;
O’Donnell 2015a;O’Donnell 2015b; Singh 2016a; Singh 2016b).
For HRQoL, the risk of detection bias was considered low for fif-
teen studies (Bateman 2013; Beeh 2014; Celli 2014; Dahl 2013;
Donohue 2013; Feldman 2012; Larbig 2015; Maltais 2014b;
Maltais 2014c; Mahler 2014; NCT00626522; NCT02275052;
Watz 2016; Troosters 2016; Zheng 2014) and unclear in seven
studies (Beeh 2015; Maltais 2014; O’Donnell 2015a; O’Donnell
2015b; Siler 2016; Singh 2016a; Singh 2016b).
Incomplete outcome data
We considered 20 of 22 studies to be at low risk of attrition bias
on the basis of low and balanced rates of participant withdrawal,
which were adequately documented in the trial reports. One study
(Dahl 2013) was considered to be at high risk for attrition bias
based on a greater than 20% rate of attrition in the placebo arm
versus < 15% in the IND/GLY arm; insufficient information was
reported by one study (Larbig 2015), resulting in a rating of unclear
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risk of attrition bias.
Selective reporting
We considered 21 of 22 studies to be at low risk of reporting bias.
One study (Larbig 2015) was considered to be at high risk for
reporting bias as the abstract (abstract only) did not report key
prespecified outcomes (as reported on the trial registry site).
Other potential sources of bias
We considered there to be potential sources of bias present in four
of the studies. In Dahl 2013, more participants in the QVA149
group had severe COPD versus those in the placebo group; how-
ever, this would likely skew treatment effect in favour of placebo.
An imbalance in baseline characteristics in Feldman 2012 sug-
gested that randomisation was not robust, although the limited
sample size of the placebo group could also account for imbalance
in baseline characteristics. In Siler 2016, a greater proportion of
participants with GOLD category D were enrolled in the active
treatment group, possibly favouring placebo and underestimation
of the treatment effect. In Zheng 2014, a higher proportion of
participants with GOLD Stage IV were enrolled in the UMEC/VI
62.5/25 µg group compared with placebo and could potentially
skew the treatment effect in favour of placebo. These four stud-
ies were considered to be at high risk of ’other’ bias; however, we
noted that in three cases, the issue would tend to skew the results
in favour or placebo, resulting in a potential underestimation of
the treatment effect.
Effects of interventions
See: Summary of findings for the main comparisonOnce-daily
LABA/LAMA in a combined inhaler compared with placebo in
adults with COPD
Structure of the meta-analysis
As per the protocol, we elected to perform a meta-analysis only
when interventions and outcomes were sufficiently similar for
pooling of the data. We subgrouped the data in the forest plots
according to the type and dose of LABA/LAMA combination.
However, some comparisons (stated below) should be interpreted
with caution because of the relatively small number of trials for
each subgrouping, heterogeneity in study design (i.e. length, in-
clusion and exclusion criteria), and the low number of events for
all-cause mortality and SAEs.
Structure of the narrative synthesis
In the following sections, we present a narrative summary of study
results according to the prespecified outcomes. We present pri-
mary outcomes (all-cause mortality, SAEs, AECOPD, respiratory
HRQoL) followed by secondary outcomes (trough FEV1, peak
FEV1, 6MWT,AEs). For each outcome, we describe the overall ef-
fect of the intervention irrespective of LABA/LAMA type or dose,
followed by the effect of the intervention in subgroups according
to LABA/LAMA type and dose.
Primary outcomes
All-cause mortality
Eighteen studies (8752 participants) reported all-cause mortality,
although the number of reported deaths was low. There was no
significant difference in the number of deaths reported in partic-
ipants receiving a once-daily LABA/LAMA fixed-dose combina-
tion compared with those receiving placebo (OR 1.88, 95% CI
0.81 to 4.36; I2 = 0%; Analysis 1.1). The overall certainty of the ev-
idence for this outcome was rated as low, having been downgraded
once for indirectness (duration of studies varied widely from six
weeks to 52 weeks) and once for imprecision (wide confidence
intervals due to a low number of events).
The results were generally consistent (i.e. overlapping CIs) across
subgroups for different LABA/LAMA combinations and doses,
with ORs ranging from 1.88 with UMEC/VI 500/25 µg to 3.12
with UMEC/VI 62.5/25µg (Figure 4); the only exception was the
UMEC/VI 125/25 µg subgroup with two deaths reported in the
placebo arm of one of four studies and no other deaths reported
in the remaining three studies, resulting in an OR of 0.14 (95%
CI 0.01 to 2.83).
16Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic
obstructive pulmonary disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 4. Forest plot of comparison: 1 LABA/LAMA versus placebo, outcome: 1.1 All-cause mortality.
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Serious adverse events
Twenty-two studies (10,536 participants) reported the number
of participants experiencing serious, but non-fatal adverse events
during the study period, for which there was no statistically sig-
nificant difference (OR 1.06, 95% CI 0.88 to 1.28; I2 = 0%;
Analysis 1.2). Compared with taking placebo, we estimated that
taking once-daily LABA/LAMA in a combined inhaler would re-
sult in three more people per 1000 experiencing a SAE, but the
confidence intervals ranged from five fewer to nine more people
per 1000. The overall certainty of the evidence for this outcome
was rated as high.
The results were generally consistent across subgroups for different
LABA/LAMA combinations and doses, with ORs ranging from
0.75 with UMEC/VI 125/25 µg to 1.29 with UMEC/VI 62.5/
25 µg (Figure 5). The only exceptions were the ACM/FOR 200/
6 µg and 200/12 µg subgroups, where the ORs were 0.51 (95%
CI 0.02 to 12.96) and 0.51 (95% CI 0.02 to 13.07), respectively;
however, these results should be interpreted cautiously as theywere
based on a small sample size from a single study, resulting in wide
confidence intervals.
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Figure 5. Forest plot of comparison: 1 LABA/LAMA versus placebo, outcome: 1.2 SAEs.
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AECOPD
Three studies (1127 participants) reported the number of par-
ticipants experiencing an AECOPD; all three studies examined
UMEC/VI versus placebo. Significantly fewer people receiving
once-daily LABA/LAMA in a combined inhaler experienced an
AECOPD compared with those receiving placebo (OR 0.53, 95%
CI 0.36 to 0.78; I2 = 0%; Analysis 1.3; Figure 6). Compared with
taking placebo, we estimated that taking once-daily LABA/LAMA
in a combined inhaler would result in 59 fewer people per 1000
experiencing an AECOPD, with the confidence intervals ranging
from 27 to 83 fewer people per 1000. The overall certainty of
the evidence for this outcome was rated as moderate, having been
downgraded once for indirectness (all studies related to UMEC/
VI). The results were consistent for two of three UMEC/VI doses
examined, withORs of 0.58 (95%CI 0.37 to 0.93) and 0.37 (0.17
to 0.78) for the 62.5/25 µg and 125/25 µg groups, respectively;
the OR for the 500/25 µg dose was 1.68 (0.08 to 35.43) but was
based on data from a small sample size (n = 51 participants).
Figure 6. Forest plot of comparison: 1 LABA/LAMA versus placebo, outcome: 1.3 AECOPD.
Two studies (1371 participants), reported the time to first AE-
COPD; both studies examined UMEC/VI 125/25 µg versus
placebo. The mean time to first AECOPD was statistically signif-
icantly longer in people receiving once-daily LABA/LAMA in a
combined inhaler compared with those receiving placebo (Hazard
Ratio 0.44, 95% CI 0.31 to 0.63; Analysis 1.4).
Health-related quality of life
SGRQ
Eight studies (4952 participants) reported health-related quality
of life as assessed using the SGRQ, at the end of treatment. A de-
crease in SGRQ represents an improvement in quality of life and
the MCID is considered to be a change of four units (SGRQ-C
Manual). At the end of treatment in participants receiving once-
daily LABA/LAMA in a combined inhaler, the mean improve-
ment versus placebo in adjusted SGRQ score was -4.08 (95% CI -
4.80 to -3.36; Analysis 1.5), which was statistically significant and
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clinically relevant, exceeding the MCID. The overall certainty of
the evidence for this outcome was rated as high.
The results were generally consistent across subgroups for differ-
ent LABA/LAMA combinations and doses, with mean differences
versus placebo ranging from -3.64 with UMEC/VI 125/25 µg to
-4.72 with TIO/OLO 5/5 µg (Figure 7). The mean difference
in SGRQ score versus placebo was statistically significant for all
LABA/LAMA combinations and doses for which data were avail-
able (IND/GLY 110/50 µg; UMEC/VI 125/25 µg; UMEC/VI
62.5/25 µg; TIO/OLO 2.5/5 µg; TIO/OLO 5/5 µg); however,
theMCID (4.00) was only exceeded with UMEC/VI 62.5/25µg,
TIO/OLO 2.5 µg and TIO/OLO 5/5 µg.
Figure 7. Forest plot of comparison: 1 LABA/LAMA versus placebo, outcome: 1.5 Difference vs placebo in
adjusted SGRQ score (HRQoL).
Seven studies (4258 participants) reported SGRQ responder sta-
tus (i.e. the proportion of participants who achieved a ≥ 4 point
improvement from baseline in SGRQ total score) at the end of
treatment. Compared with placebo, a greater proportion of par-
ticipants receiving once-daily LABA/LAMA were responders (OR
1.75, 95% CI 1.54 to 1.99; I2 = 0%; Analysis 1.6) and this differ-
ence was statistically significant. Compared with taking placebo,
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we estimated that taking a once-daily LABA/LAMA in a com-
bined inhaler would result in 138 more people per 1000 achieving
a clinically meaningful improvement in quality of life, with the
confidence intervals ranging from 106 to 170 more people per
1000. This finding is in agreement with the mean improvement
in SGRQ total score for LABA/LAMA versus placebo, as reported
above. The results were generally consistent across subgroups for
different LABA/LAMA combinations and doses, with ORs versus
placebo ranging from 1.70 with UMEC/VI 62.52/5 µg to 2.35
with TIO/OLO 5/5 µg; the exception was IND/GLY 110/50 µg
forwhich theOR(95%CI) versus placebowas 1.35 (0.98 to 1.86),
thus narrowly missing out on statistical significance. We note that
the latter result was based on a single study, for which data were
presented as percentages and extrapolated to participant numbers;




Adjusted difference versus placebo in trough FEV1 at end of
treatment
Thirteen studies (6598 participants) reported adjusted trough
FEV1 at the end of treatment (i.e. change from baseline in FEV1).
In participants receiving once-daily LABA/LAMA in a combined
inhaler, the mean difference versus placebo in adjusted trough
FEV1 was 0.20 L (95% CI 0.19 to 0.21; Analysis 1.7), which
was statistically significant and clinically relevant, exceeding the
MCID of 100 mL (Donohue 2005). The overall certainty of the
evidence for this outcome was rated as moderate, having been
downgraded once for inconsistency (significant heterogeneity, I2=
71%), noting that heterogeneity was due to a different magnitude
of treatment effect in a single study (NCT00626522; see below).
The results were generally consistent (i.e. overlapping CIs) across
subgroups for different LABA/LAMA combinations and doses,
with mean differences versus placebo ranging from 0.18 L with
UMEC/VI 62.5/25 µg to 0.25 L with IND/GLY 110/50 µg; the
exception was the results for ACLID/FORM, which were based
on a single study (NCT00626522); mean differences were 0.07,
0.12 and 0.07 L for the 200/6, 200/12 and 200/18 µg subgroups,
respectively. The MCID (0.1 L) was exceeded with IND/GLY
110/50 µg, UMEC/VI 62.5/25 µg, UMEC/VI 125/25 µg, TIO/
OLO 2.5 µg, and TIO/OLO 5/5 µg.
Unadjusted difference versus placebo in trough FEV1 at end
of treatment
Five studies (2330 participants) reported trough FEV1 at the end
of treatment (i.e. not adjusted for baseline values). In participants
receiving once-daily LABA/LAMA in a combined inhaler, the
mean difference versus placebo in trough FEV1 was 0.18 L (95%
CI 0.16 to 0.20; Analysis 1.8), which was statistically significant
and clinically relevant, exceeding theMCID of 100 mL (Donohue
2005). The overall certainty of the evidence for this outcome was
rated as high.
The results were consistent across subgroups for different LABA/
LAMA combinations and doses, with mean differences versus
placebo ranging from 0.16 L with TIO/OLO (2.5/5 and 5/5 µg
doses) to 0.20 L with IND/GLY 110/50 µg. The MCID (0.1L)
was exceededwith all LABA/LAMAcombinations/doses forwhich
data were available (IND/GLY 110/50 µg; TIO/OLO 2.5/5 µg;
TIO/OLO 5/5 µg).
Pooled analyses for trough FEV1
When the adjusted and unadjusted data for trough FEV1 were
pooled, there was no appreciable change in the overall mean dif-
ference (adjusted: MD 0.20 L, 95% CI 0.19 to 0.21; unadjusted:
0.18 L, 95% CI 0.16 to 0.20; pooled: MD 0.20 L, 95% CI 0.19
to 0.20 Analysis 1.9).
Adjusted peak FEV1
Seven studies (4188 participants) reported peak FEV1 at the end
of treatment (i.e. peak FEV1 was explicitly specified, rather than
1-hour FEV1, 2-hour FEV1, etc). In participants receiving once-
daily LABA/LAMA in a combined inhaler, the mean difference
versus placebo in peak FEV1 was 0.31 L (95% CI 0.29 to 0.32;
Analysis 1.10), which was statistically significant. The overall cer-
tainty of the evidence for this outcome was rated as moderate,
having been downgraded once for inconsistency (significant het-
erogeneity, I2= 68%).
The results were consistent across subgroups for different LABA/
LAMA combinations and doses, with mean differences versus
placebo ranging from 0.22 L with UMEC/VI 62.52/5 µg to 0.35
L with IND/GLY 110/50 µg.
6MWT
No studies reported data for this outcome.
Adverse events
Seventeen studies (8235 participants) reported the number of par-
ticipants experiencing adverse events during the study period, for
which there was no statistically significant difference (OR 0.95,
95% CI 0.86 to 1.04; I2 = 0%; Analysis 1.11). Compared with
taking placebo, we estimated that taking once-daily LABA/LAMA
in a combined inhaler would result in 13 fewer people per 1000
experiencing a AE, with the confidence intervals ranging from 37
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fewer to 10 more people per 1000. The overall certainty of the
evidence for this outcome was rated as high.
The results were generally consistent across subgroups for different
LABA/LAMA combinations and doses, with ORs ranging from
0.78 with TIO/OLO 5/5 µg to 1.08 with UMEC/VI 125/25 µg
(Figure 5). The only exception was the UMEC/VI 500/25 µg
subgroup (OR 2.84, 95% CI 0.32 to 25.36; participants = 51);
however, these results should be interpreted cautiously as theywere
based on a small sample size from a single study, resulting in wide
confidence intervals.
Subgroup analyses
Participants with ICS use during the trial versus participants
without ICS use during the trial
All studies permitted the use of ICS during the trial, provided that
participants had used ICS prior to the trial, and, in some cases,
that the dose was stable prior to study initiation. Therefore, no
subgroup analysis was performed.
Different LABA/LAMA combinations
The main analyses were split out by different LABA/LAMA com-
binations; please see the main results section above for a summary
of different LABA/LAMA combinations.
Length of follow-up (less than six months versus six months
or longer)
Three studies had a duration of six months or longer (Bateman
2013; Dahl 2013; Larbig 2015) and all evaluated IND/GLY 110/
50 versus placebo. This subanalysis was only relevant for three
of the four primary outcomes as no studies evaluating IND/GLY
contributed data to the meta-analyses for AECOPD.
For all-cause mortality, no significant difference between LABA/
LAMA and placebo groups was identified, regardless of study du-
ration (overall: < 6 months, OR 1.86, 95% CI 0.75 to 4.60 (25
studies);≥ 6 months, OR 2.03, 95%CI 0.22 to 18.35 (2 studies);
IND/GLY: < 6 months, OR 2.97, 95% CI 0.47 to 18.97 (3 stud-
ies); ≥ 6 months, OR 2.03, 95% CI 0.22 to 18.35 (2 studies))
(Analysis 2.1; Analysis 3.1).
For SAEs, there was no statistically significant difference in the
number of participants experiencing serious, but non-fatal, ad-
verse events during the study period, regardless of study duration
(overall: < 6 months, OR 1.02, 95% CI 0.80 to 1.29 (19 studies);
≥ 6 months, OR 1.14, 95% CI 0.83 to 1.56 (3 studies); IND/
GLY: < 6 months, OR 1.35, 95% CI 0.54 to 3.40 (3 studies); ≥
6 months, OR 1.14, 95% CI 0.83 to 1.56 (3 studies)) (Analysis
2.2; Analysis 3.2).
For HRQoL, a statistically significant and clinically relevant im-
provement (i.e. exceeding MCID) in SGRQ score was observed
with LABA/LAMA compared with placebo based on studies with
a duration of < 6 months (MD -4.15, 95% CI -4.99 to -3.32; 9
studies). Three studies with a duration of ≥ 6 months reported
SGRQ score and all evaluated IND/GLY 110/50 µg. As in the
primary analyses, a statistically significant improvement was ob-
served but did not exceed the MCID (MD -3.88, 95% CI -5.30
to -2.45; 2 studies).
For each outcome (all-cause mortality, SAEs, and HRQoL), given
the overlapping confidence intervals for the < 6-month versus ≥
6-month comparison, we concluded that study duration had no
statistically significant effect on the results.
Baseline COPD severity
All of the included studies that contributed data to the quantitative
analyses enrolled a majority (> 97%) of participants with GOLD
Stage II/III COPD. Therefore, subanalyses based on baseline dis-
ease severity were not performed.
Sensitivity analyses
The following sensitivity analyses were performed for the primary
outcomes.
Available case analysis versus true ITT analysis
All included studies claimed to analyse the ITT population or ’full
analysis set’; however, in the majority of studies it was not possible
to determine whether missing values were imputed. Therefore,
this sensitivity analysis was not performed.
Fixed- versus random-effect models
The results were consistent regardless of choice of analysis model
(fixed- versus random-effects model) (Table 2).
Risk of bias assessments
The results were consistent regardless of the inclusion of studies
with a high risk of bias for one or more domains (i.e. any risk of
bias versus low/unclear risk of bias) (Table 3).
D I S C U S S I O N
Summary of main results
We included twenty-two studies (13 parallel-group designs and
nine cross-over designs), which randomised a total of 8461 par-
ticipants. All studies were RCTs that compared once-daily LABA/
LAMA via combination inhaler (n = 6252) with placebo (n =
3819). Most participants were adults with GOLD stage II/III
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COPD and between 28% to 58% of participants were using ICS
at baseline. The duration of treatment ranged from three to 52
weeks (mean = 11 weeks; median = 12 weeks) and only three stud-
ies had a duration of six months or longer. All studies were per-
formed atmultiple centres and 19 of 22 studies were international.
Most studies were well designed and considered to be at low risk
of bias. Compared to placebo, once-daily LABA/LAMA in a com-
bined inhaler resulted in an improvement in HRQoL (measured
using the SGRQ) and lung function and a decrease in AECOPD.
Generally, the safety and tolerability of once-daily LABA/LAMA
appeared comparable to that observed in placebo-treated partici-
pants, with similar rates of AEs and SAEs observed in each group.
There was no significant difference in the number of deaths re-
ported in participants receiving a once-daily LABA/LAMA fixed-
dose combination (one per 1000) compared with those receiving
placebo (2 per 1000); we assessed the certainty of the evidence
to be low having been downgraded for imprecision and indirect-
ness. Treatment effects were generally consistent across different
LABA/LAMA combinations and doses. Improvements inHRQoL
that statistically significantly exceeded the MCID were achieved
with UMEC/VI 62.5/25 µg and TIO/OLO (2.5/5 and 5/5 µg)
but not with IND/GLY 110/50 µg or UMEC/VI 125/25 µg.
Improvements in lung function (trough FEV1 and peak FEV1)
that statistically significantly exceeded the MCID were achieved
with IND/GLY 110/50 µg, UMEC/VI (62.5/25 and 125/25 µg)
and TIO/OLO (2.5/5 and 5/5 µg); these findings should be in-
terpreted cautiously given the uncertainty around the MCID for
FEV1 (see Types of outcome measures). A clinically significant
improvement in peak FEV1, but not trough FEV1, was observed
with ACLID/FORM, although the evidence for this combination
was based only on a single study with a relatively small sample
size. A statistically significant reduction in both the time to first
AECOPD and rate of AECOPD was observed with UMEC/VI;
data for these AECOPD outcomes were not available for other
combinations.
Overall completeness and applicability of
evidence
Demographics across the 8641 randomised participants were rep-
resentative of patients with COPD (GOLD 2017). For example,
participants had a mean age of around 60 to 65 years, were more
often male and the majority either currently smoked or had a his-
tory of smoking. The inclusion criteria for 21 of 22 included stud-
ies specified either GOLD stage II/III, or criteria aligned with this
disease severity; only one of the included studies permitted the
enrolment of individuals with moderate-to-severe COPD. There-
fore, the evidence synthesised herein is applicable to individuals
with mild-to-moderate COPD. All prespecified outcomes, except
for the 6MWT, were well reported across the 22 studies, although
reporting of the number of participants experiencing AECOPD
was based on only three studies and time to first AECOPD on
only two studies; this was taken into account when evaluating
the strength of the evidence for these outcomes. Six studies evalu-
ated the once-daily combination of IND/GLY (110/50 µg), seven
studies evaluatedTIO/OLO (2.5/5 or 5/5µg), eight studies evalu-
ated UMEC/VI (62.5/5 µg, 125/25 or 500/25 µg) and one study
evaluated ACD/FOR (200/6, 200/12 or 200/18 µg). Subgroup-
ing of studies by LABA/LAMA combination and dose had the
effect of reducing the sample size for each comparison; in partic-
ular, only one study with a short duration examined the ACLID/
FORM combination so we can be less certain of how the overall
findings apply to the ACLID/FORM combination. The median
study duration was 12 weeks; only three studies had a duration of
six months or longer and all evaluated ING/GLY 110/50 µg. In
these studies with a duration of six months or longer, the results
of meta-analyses for all-cause mortality, SAEs, and HRQoL were
consistent with those based on studies with a duration of less than
six months.
Quality of the evidence
The certainty of the evidence was generally considered to be mod-
erate or high with the exception of all-cause mortality, which we
considered to be low, having downgraded it once for indirect-
ness and once for imprecision due to a low number of events. We
considered the certainty of the evidence for SAEs, HRQoL, and
AEs to be high. The certainty of the evidence for lung function
(trough and peak FEV1) was considered to be moderate having
been downgraded for inconsistency due to significant heterogene-
ity. The certainty of the evidence for AECOPD was considered
moderate having been downgraded once for indirectness as the
evidence related only to UMEC/VI. We could not rule out the
possibility of publication bias for this outcome but were unable to
demonstrate conclusively that publication bias existed, due to the
low number of studies reporting this outcome (i.e. the validity of
a funnel plot is limited when based on fewer than ten studies). Ad-
ditionally, selective reporting for this outcome in studies of other
LABA/LAMA combinations did not occur based on comparison
of primary reports with trial registry entries.
Risk of bias in the included studies was generally considered to
be low or was unclear due to the lack of necessary information
provided in the study reports. Across 198 assessments (22 studies,
nine domains each), over three-quarters were considered to be at
a low risk of bias, and only seven were considered to be at a high
risk of bias. Risk of bias was considered unclear in the remaining
37 assessments. Four studies were considered to be at high risk
for ’other’ bias, in three cases, due to greater disease severity in
the LABA/LAMA group compared with the placebo group; this
problem would tend to skew the results in favour or placebo,
resulting in a potential underestimation of the treatment effect.
However, the results were robust to the removal of studies with any
domain considered to be at high risk of bias and no downgrading
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of the strength of the evidence (by GRADE) was performed on
the basis of risk of bias.
Potential biases in the review process
The review was conducted to the standards set by MECIR
(MECIR 2018) and in accordance with the published protocol. In
particular, two authors independently screened the search results,
determined studies for inclusion, assessed the risk of bias, extracted
the relevant data, and performed the GRADE assessment (i.e. all
steps involving subjective decisions). There were several minor
deviations from the protocol (see Differences between protocol
and review). It is unlikely that any relevant studies were missed,
as a skilled information specialist conducted the main electronic
searches. Additionally, the main searches were supplemented by
manual searches of reference lists of associated studies and reviews.
Finally, this review has undergone editorial and peer review and
thus considers the opinions of independent external experts. In
summary, the review was conducted in a manner that should en-
sure that our conclusions fairly and accurately represent the results
synthesised during the review process.
Agreements and disagreements with other
studies or reviews
The majority of relevant systematic reviews compared LABA/
LAMA FDCs with their mono-components (Calzetta 2016;
Calzetta 2017). However, our findings are consistent with those
of a recent network meta-analysis of LABA/LAMA versus their
mono-components and placebo (Oba 2016). For example, LABA/
LAMA combinations demonstrated a mean improvement in
trough FEV1 over placebo of 0.21 (95% CI 0.19, 0.23), 0.20 L
(95%CI0.17 to 0.23) and0.24 L (95%CI0.14 to 0.35) at three,
six, and 12months, respectively, agreeing with the 0.20 L reported
herein. Clinically significant improvements in HRQoL were also
seen with LABA/LAMA over placebo, with a mean change from
baseline in SGRQ score of -4.6 (-5.9, -3.3) at three months and
-4.1 (-5.9, -2.3) at six months, agreeing with the 4.08 point im-
provement reported herein. Furthermore and in agreement with
our findings, no significant differences in mortality or total SAEs
were observed between LABA/LAMA and placebo (Oba 2016).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Compared with placebo, once-daily LABA/LAMA (either IND/
GLY, UMEC/VI or TIO/OLO) via a combination inhaler is asso-
ciated with a clinically significant improvement in lung function
and health-related quality of life in patients with mild-to-moder-
ate COPD; in addition, UMEC/VI appears to reduce the rate of
exacerbations in this population. These conclusions are supported
by moderate- or high-certainty evidence from studies with an ob-
servation period of up to one year.
Implications for research
Prespecified outcomes of interest for this review were generally
well evaluated by the included studies, with the exception of the
6MWT, which was not evaluated by any of the studies. The
6MWT requires large sample sizes or large treatment effects to
detect a statistically significant signal and thus may not be the
most appropriate test for evaluating new interventions; alternative
outcomes for assessing functional exercise capacity include the in-
cremental shuttle walk test and the endurance shuttle walk test
(Singh 2014b). Future research should focus on establishing the
relative net clinical benefit (i.e. considering both efficacy and sa-
fety) for the different LABA/LAMA combinations; the findings of
this review (relative to placebo) should facilitate this work.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bateman 2013
Methods Study IDanddates performed:NCT01202188 (SHINE); September 2010 toFebruary
2012.
Study design: Randomised, double-blind, parallel-group, placebo and active controlled
study
Duration of study: Pre-randomisation period (pre-screening + run-in): 3 weeks; treat-
ment period: 26 weeks
Study setting, location, number of centres: 166 academic and clinical research centres
in Europe, North America, South America, Asia (Philippines, Japan, India), Australia,
China, Taiwan. and South Africa
Key inclusion criteria: Adults aged≥ 40 years; signed consent; symptomatic moderate-
to-severe stable COPD (GOLD 2008 Stage II or III); current or ex-smokers (≥ 10 pack
years); post-BD FEV1≥ 30% and < 80% predicted normal AND post-BD FEV1/FVC
< 0.7 at visit 2 (day 14)
Key exclusion criteria: Pregnant or women of child bearing potential; concomitant
pulmonary disease; history of asthma; lung cancer or history of lung cancer; history
of long QT syndrome; Type I or uncontrolled Type II diabetes; contraindication to or
hypersensitive to anticholinergics, LABA, sympathomimetic amines, or lactose
Concomitant medications: Permitted: SSRI stable regimen≥ 1 month prior to screen-
ing or during study; inactivated vaccine (not within 48 hours of study visit); ICS (con-
stant doses and dose regimens of ≥ 1 month); H1 antagonists (constant doses and dose
regimens). Excluded: long term O2 therapy.
Participants N randomised: IND/GLY 110/50 µg: 475; placebo: 234.
N analysed: IND/GLY 110/50 µg: 474; placebo: 232.
Mean age (SD), years: IND/GLY 110/50 µg: 64.0 (8.9); placebo: 64.4 (8.6).
Gender male, n/N (%): IND/GLY 110/50 µg: 362/474 (76.4); placebo: 169/232 (72.
8).
Baseline lung function - mean (SD) post-BD% predicted FEV1, %: IND/GLY 110/
50 µg: 55.7 (13.2); placebo: 55.2 (12.7).
Smoking status (current), n/N (%): IND/GLY 110/50 µg: 192/474 (40.5); placebo:
93/232 (40.1).
Interventions Intervention: Once-daily QVA149 (IND/GLY 110/50 µg).
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Trough FEV1 at week 26. Secondary: SGRQ score
(week 26); SGRQ score week 12 and week 26; and number of participants with aMCID
(4 units) improvement frombaseline in SGRQ score (week 26); rate ofmoderate or severe
COPD exacerbation; percentage of participants with ≥ 1 moderate or severe COPD
exacerbation (26 weeks); AEs; SAEs
Reported outcomes: all prespecified outcomes reported.
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Bateman 2013 (Continued)
Notes Funding for trial; notable author COIs: The study was funded by Novartis Pharma
AG. Authors were employed by Novartis or had received remuneration from Novartis
for advisory boards/lectures
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible participants were assigned a ran-
domisation number via IRT system, link-
ing the patient to a treatment arm and
specific unique medication number for the
study drug. The randomisation number
was not communicated to the investigator
contacting the IRT
Allocation concealment (selection bias) Low risk See random sequence generation.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants, investigator staff,
personnel performing assessments and data
analysts was maintained by ensuring ran-
domisation data remained strictly confi-
dential and inaccessible to anyone involved
in the study until the time of unblind-
ing. In addition, the identity of the treat-
ments was concealed by the use of study
drugs that were all identical in packaging,
labelling, and schedule of administration,
appearance, taste, and odour
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Knowledge of treatment allocation by par-
ticipant or personnel would be unlikely to
influence objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of personnel performing assess-
ments and data analysts was maintained
by ensuring randomisation data remained
strictly confidential and inaccessible to any-
one involved in the study until the time
of unblinding. In addition, the identity of
the treatments was concealed by the use of
study drugs that were all identical in pack-
aging, labelling, and schedule of adminis-
tration, appearance, taste, and odour
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
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Bateman 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was low and consistent between
treatment arms.
Selective reporting (reporting bias) Low risk Comparison of trial registration and pub-
lished report information performed. Pre-
specified outcomes were well reported
Other bias Low risk None identified.
Beeh 2014
Methods Study ID and dates performed:NCT01294787 (BRIGHT); study dates not reported.
Study design: Multicentre, randomised, double-blind, double-dummy, placebo-con-
trolled, three-period cross-over study
Duration of study: 18-25 day run-in period; 3 x 3-week treatment period, 21-day
washout period between treatments
Study setting, location, number of centres: Not reported.
Key inclusion criteria: Participants≥ 40 years of age; moderate-to-severe COPD (Stage
II or III according to GOLD 2008 criteria); smoking history of≥ 10 pack years (current
or ex-smokers); post-bronchodilator FEV1 of ≥ 40% and < 70%
Key exclusion criteria: Pregnant women or nursing mothers; women of child-bearing
potential; contraindication for treatment with, or having a history of reactions/ hyper-
sensitivity to any of the following inhaled drugs or drugs of a similar class: anticholinergic
agents, long and short acting beta-2 agonists, sympathomimetic amines, lactose or any of
the other excipients; a history of longQT syndrome or whoseQTcmeasured at screening
(Fridericia method) is prolonged (> 450 ms for males and females) as confirmed by the
central ECG assessor; a clinically significant abnormality on the screening ECG; Type I
or uncontrolled Type II diabetes; Wmax value < 20W (as determined by the incremental
cycle endurance test) at visit 2); body mass index < 15 or > 40 kg/m2; contraindication to
cardiopulmonary exercise testing; resting (5 min) oxygen SaO2 saturation on room air of
< 85%; participants who do not maintain regular day/night, waking/sleeping cycles (e.g.
night shift workers); participants whose endurance in the exercise test is limited by non-
respiratory conditions e.g. by neurologic, orthopaedic, or other disorders, narrow-angle
glaucoma, symptomatic prostatic hyperplasia or bladder-neck obstruction or moderate
to severe renal impairment or urinary retention; a history of malignancy of any organ
system (including lung cancer); clinically relevant laboratory abnormality or a clinically
significant condition
Concomitant medications: Short-acting bronchodilators (salbutamol or albuterol) were
provided for rescue use throughout the study but were not permitted within 6 hours of
each visit. Prior ICS use permitted
Participants Note: cross-over study therefore participant data reported for whole cohort
N randomised: 85
N analysed: 77
Mean age (SD), years: 62.1 (8.11)
Gender - male, n/N (%): 53/84 (63.1)
Baseline lung function - post-bronchodilator % predicted FEV1: 46.5 (10.30)
Smoking status, current smoker, n/N (%): 45 (53.6)
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Beeh 2014 (Continued)
Interventions Intervention: Once-daily IND/GLY (QVA149) 110/50 µg
Comparator: Once-daily placebo
Outcomes Prespecified outcomes: Primary: exercise tolerance comparison between QVA149 and
placebo groups at 3 weeks. Secondary (all QVA149 vs placebo): dynamic inspiratory
capacity at 3 weeks; trough 24-hour post-dose inspiratory capacity at 3 weeks; trough
24-hour post-dose FEV1 at 3 weeks; residual volume, slow vital capacity, specific airway
conductance and functional residual capacity, each on day 1 and day 21, at 5 min
and 15 min post-dose as determined by body plethysmography; dynamic inspiratory
capacity post-dose pre-exercise after three weeks of treatment; exertional dyspnoea (Borg
CR10 Scale) at 3 weeks; leg discomfort (Borg CR10 Scale) during submaximal constant
load cycle ergometry test after three weeks treatment; exercise endurance time during
submaximal constant load cycle ergometry test cycle exercise test on day 1
Reported outcomes: prespecified outcomes well reported.
Notes Funding for trial; notable author COIs: Novartis Pharma AG funded this study. All
authors had relevant conflicts of interest relating to funding or employment provided by
Novartis Pharma AG
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk IRT system was used to assign randomisa-
tion.
Allocation concealment (selection bias) Low risk IRT system was used to assign randomisa-
tion.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Personal communication from Dr Beeh (7
August 2018) confirmed that personnel
and participants were blinded to treatment
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Personal communication from Dr Beeh (7
August 2018) confirmed that personnel
and participants were blinded to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Personal communication from Dr Beeh (7
August 2018) confirmed that outcome as-
sessors were blinded to treatment
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Personal communication from Dr Beeh (7
August 2018) confirmed that outcome as-
sessors were blinded to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout rate was low (~15%) and similar
between QVA149 and placebo arms
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Beeh 2014 (Continued)
Selective reporting (reporting bias) Low risk Prespecified outcomes were generally well
reported.
Other bias Low risk Safety results were analysed according to
treatment received. No other issues identi-
fied
Beeh 2015
Methods Study ID and dates performed: NCT01559116; VIVACITO; dates not reported.
Study design: Double-blind, placebo-controlled, multicentre, Phase III, incomplete
cross-over study
Duration of study: 38-42 weeks including 2-6 week run-in period. Each treatment
given for 6 weeks
Study setting, location, number of centres: 29 centres in seven countries (Belgium,
Canada, Denmark, Germany, Hungary, The Netherlands, and the USA)
Key inclusion criteria: A diagnosis of COPD; aged ≥ 40 years; smoking history of ≥
10 pack-years; relatively stable airway obstruction with a post-bronchodilator FEV1 <
80% of predicted normal (in German sites only, FEV1≥ 30%) and FEV1/FVC < 70%
of predicted normal
Key exclusion criteria: History of asthma or significant disease other than COPD;
unstable or life-threatening cardiac arrhythmia; hospitalisation for heart failure within
the past year; history of myocardial infarction within 1 year of screening or a history of
life-threatening pulmonary obstruction
Concomitant medications: Participants could continue on inhaled corticosteroids dur-
ing treatment periods (if taken as maintenance treatment at study entry) but not anti-
cholinergics or LABAs. Short-acting anticholinergics were permitted during screening
and the washout periods, but had to be stopped 8 h before pulmonary function test at the
first visit of the next treatment period. LAMAs and LABAs were not permitted during
washout or screening periods. Open-label salbutamol was provided to participants as
rescue medication to be used at baseline and during screening, treatment, washout, and
follow-up periods
Participants Note: incomplete cross-over study therefore participant data reported for whole
cohort
N randomised: N = 219
N analysed: TIO/OLO 2.5/5 µg: n = 135 ; TIO/OLO 5/5 µg: n = 138 ; placebo: n =
130
Mean age (SD), years: 61.1 (7.7)
Gender - male, n/N (%): 129 (58.9%)
Baseline lung function - mean (SD) pre-bronchodilator FEV1, L: 1.361 (0.471)
Smoking status, current smoker, n/N (%): 137/219 (62.6)
Interventions Intervention: Once-daily TIO/OLO 2.5/5 µg; once-daily TIO/OLO 5/5 µg.
Comparator: Once-daily placebo.
48Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic
obstructive pulmonary disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Beeh 2015 (Continued)
Outcomes Prespecified outcomes: Primary: FEV1 AUC 0-24 h response after 6 weeks treatment.
Secondary (each after 6 weeks of treatment): FEV1 AUC 0-12h response; FEV1 AUC
12-24 h response; trough FEV1 response; peak (0-3 h) FEV1 response; FVC AUC 0-
24 h response; FVC AUC 0-12 h response; FVC AUC 12-24h response; trough FVC
response; peak (0-3h) FVC response; safety
Reported outcomes: All prespecified outcomes were reported, plus functional residual
capacity, residual volume, inspiratory capacity, and total lung capacity
Notes Funding for trial; notable author COIs: This study was funded by Boehringer Ingel-
heim Pharma GmbH& co. KG. Three of seven authors were employees of the company
that funded the study; the remaining authors received no compensation in relation to
development of the manuscript (no COIs provided)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided.
Allocation concealment (selection bias) Unclear risk Insufficient information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided (‘dou-
ble-blind’ stated but did not specify partic-
ipant, personnel or outcome assessor)
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Knowledge of treatment allocation by par-
ticipant or personnel would be unlikely to
influence objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided (‘dou-
ble-blind’ stated but did not specify partic-
ipant, personnel or outcome assessor)
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was low and consistent between
the groups, with the highest group dropout
acknowledged as 5.8%
Selective reporting (reporting bias) Low risk Comparison of trial registration and pub-
lished report information performed. Pre-
specified outcomes were well reported
Other bias Low risk None identified.
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Celli 2014
Methods Study ID and dates performed: NCT01313637; March 22, 2011 to April 19, 2012.
Study design: Multicentre, randomised, placebo-controlled, double-blind, parallel-
group study
Duration of study: 24 weeks.
Study setting, location, number of centres: 153 centres in 14 countries.
Key inclusion criteria: Aged ≥ 40 years; history of COPD (ATS/ERS); current or
former smoker with a history of ≥10 pack-years; post-albuterol (salbutamol) FEV1/
FVC ratio < 0.70, FEV1 ≤ 70% predicted normal; a score of ≥ 2 on modified MRC
dyspnoea scale at screening
Key exclusion criteria: Not reported.
Concomitant medications: Not reported.
Participants N randomised: UMEC/VI 125/25 µg: n = 403 ; placebo: n = 275.
N analysed:UMEC/VI 125/25 µg: 403/403 (100; ITT) ; placebo: 275/275 (100; ITT)
Mean age (SD), years: UMEC/VI 125/25 µg: 63.4 (8.08); placebo: 62.2 (8.53).
Gender - male, n/N (%): UMEC/VI 125/25 µg: 264/403 (66); placebo: 175/275 (64)
.
Baseline lung function - mean (SD) post-bronchodilator % predicted FEV1:
UMEC/VI 125/25 µg: 47.7 (12.53); placebo: 47.6 (12.47).
Smoking status, current smoker, n/N (%): UMEC/VI 125/25 µg: 200/403 (50);
placebo: 143/275 (52).
Interventions Intervention: Once-daily UMEC/VI 125/25 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Change from baseline in trough FEV1 on day 169
(week 24). Secondary: Mean transition dyspnoea index focal score at day 168 (week
24); change from baseline in weighted mean 0-6 hour FEV1 obtained post-dose at day
168; safety. Other: change from baseline in the mean Shortness of Breath with Daily
Activities score for week 24
Reported outcomes: All prespecified outcomes were reported, plus: the proportion of
participants achieving an increase in FEV1 of ≥ 12% and ≥ 0.200 L above baseline at
any time during 0-6 hours post-dose on day 1; the proportion of participants achieving
an increase of ≥ 0.100 L above baseline in trough FEV1, LSM peak FEV1, serial FEV1
and serial and trough FVC; SGRQ score and time to first COPD exacerbation. Serial
FVC 0-24 h post-dose was obtained in a subset of participants
Notes Funding for trial; notable author COIs:GSK funded the design/conduct of the study
and manuscript development. All authors had received funding from, or were past or
present employees, of GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided.
Allocation concealment (selection bias) Unclear risk Insufficient information provided.
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masking quadruple (participants, care
provider, investigator, outcome assessor)
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Knowledge of treatment allocation by par-
ticipant or personnel would be unlikely to
influence objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Masking quadruple (participants, care
provider, investigator, outcome assessor)
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates were high and unbal-
anced between groups; however, ITT anal-
ysis performed
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias Low risk None identified.
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Dahl 2013
Methods Study ID and dates performed: NCT01120717 (ENLIGHTEN); study dates not
reported.
Study design: Multicentre, randomised, double-blind, parallel-group, placebo-con-
trolled study
Duration of study: 55 weeks (7-day pre-screening; 14-day run-in period; 52-week
treatment period)
Study setting, location, number of centres: Academic and clinical research centres in
Europe, Canada, Asia (India, Korea) and South Africa
Key inclusion criteria: Aged≥ 40 years of age; moderate-to-severe COPD (Stage II or
III according to the GOLD 2008 criteria); smoking history of ≥ 10 pack-years; post-
bronchodilator FEV1 of ≥ 30% and < 80% of the predicted normal and post-bron-
chodilator FEV1/FVC < 0.70 at screening; total daily symptom score of≥ 1 (obtained by
adding the scores for the morning and evening symptoms (i.e. cough, wheezing, sputum
production/colour, shortness of breath)) on 4 of the last 7 days prior to randomisation
Key exclusion criteria:COPD exacerbations that required treatment with antibiotics or
oral steroids or hospitalisation in the 6 weeks prior to screening or between screening and
randomisation; respiratory tract infection 4 weeks before or during screening; history of
asthma; a clinically significant ECG abnormality
Concomitant medications: No participants received placebo treatment in isolation at
any time during the study: placebo was included in participants’ established background
COPD therapy (e.g. daily ICS). The short-acting bronchodilator salbutamol (albuterol)
was provided for rescue use throughout the study. participants were not permitted to
use short-acting (LAMAs, LABAs, theophylline) before the screening period (for at least
7 days for LAMAs and theophylline; 48 h for LABA and LABA/ICS combinations) or
during the study. ICS use was maintained (i.e. participants taking combined LABA/ICS
at screening were transitioned to the equivalent ICS monotherapy)
Participants N randomised: IND/GLY 110/50 µg: n = 226; placebo: n = 113.
N analysed, n/N (%): IND/GLY 110/50 µg: 194/226 (85.8); placebo: 89/113 (78.8).
Mean age (SD), years: IND/GLY 110/50 µg: 62.5 (8.81); placebo: 62.9 (8.14).
Gender - male, n/N (%): IND/GLY 110/50 µg: 174/225 (77.3); placebo: 86/113 (76.
1).
Baseline lung function - post-bronchodilator % predicted FEV1: IND/GLY 110/50
µg: 56.39 (13.27); placebo: 59.43 (12.50).
Smoking status, current smoker, n/N (%): IND/GLY 110/50 µg: 102/225 (45.3);
placebo: 51/113 (45.1).
Interventions Intervention: Once-daily IND/GLY 110/50 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Number of participants with AEs, SAEs or death.
Secondary: Pre-dose FEV1 at 52 weeks; number of participants with newly occurring
or worsening clinically notable haematology values at any time point over the whole
treatment period; number of participants with newly occurring or worsening clinically
notable biochemistry values at any time point over the whole treatment period; number
of participants with newly occurring or worsening clinically notable vital signs values at
any time point over the whole treatment period; number of participants with notable
change frombaseline inFridericia’sQTc values at any time point over thewhole treatment
period
52Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic
obstructive pulmonary disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dahl 2013 (Continued)
Reported outcomes: All prespecified outcomes (see above) reported.
Notes Funding for trial; notable author COIs: The study was funded by Novartis Pharma
AG. All authors had previously received funding/compensation from Novartis or were
employees of Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided.
Allocation concealment (selection bias) Unclear risk Insufficient information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masking quadruple (participants, care
provider, investigator, outcome assessor)
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Knowledge of treatment allocation by par-
ticipant or personnel would be unlikely to
influence objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Masking quadruple (participants, care
provider, investigator, outcome assessor)
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk High rates of attrition (> 20%) noted in
placebo arm (versus < 15% in QVA149
arm). mITT analysis performed based on
full analysis set (all participants randomised
to treatment and who received at least one
dose)
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias High risk More participants in the QVA149 group
had severe COPD versus those in the
placebo group (note: this would likely skew
treatment effect in favour of placebo)
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Donohue 2013
Methods Study ID and dates performed: NCT01313650. 30 March 2011 to 5 April 2012.
Study design: Randomised, double-blind, placebo-controlled, multicentre, parallel-
group study
Duration of study: 24 weeks.
Study setting, location, number of centres: 163 centres in 13 countries.
Key inclusion criteria: Current or former cigarette smokers; aged > 40 years; clinically
established history of COPDcharacterised by airflow limitation that is not fully reversible
(ATS/ERS criteria) and documented based on a smoking history of ≥ 10 pack years;
post-salbutamol FEV1/FVC ratio < 0.70; post-salbutamol FEV1 of≤ 70% of predicted
normal values; dyspnoea score ≥ 2 on modified MRC dyspnoea scale
Key exclusion criteria:Current diagnosis of asthma or other known respiratory disorder;
abnormal or clinically significant electrocardiogram or 24-hour Holter ECG; clinically
significant clinical laboratory finding
Concomitant medications: Permitted: Inhaled salbutamol as rescue medication; ICS at
a stable dose of ≤ 1000 µg/day fluticasone propionate or equivalent from 30 days prior
to screening onward
Participants N randomised: UMEC/VI 62.5/25 µg: N = 413; placebo: N = 280.
N analysed, n/N (%): UMEC/VI 62.5/25 µg: 413/413 (100); placebo: 280/280 (100)
.
Mean age (SD), years: UMEC/VI 62.5/25 µg: 63.1 (8.71); placebo: 62.2 (9.04).
Gender - male, n/N (%):UMEC/VI 62.5/25 µg: 305/413 (74); placebo: 195/280 (70)
.
Baseline lung function - mean (SD) post-bronchodilator % predicted FEV1:
UMEC/VI 62.5/25 µg: 47.8 (13.19); placebo:46.7 (12.71).
Smoking status, current smoker, n/N (%): UMEC/VI 62.5/25 µg: 203/413 (49);
placebo: 150/280 (54).
Interventions Intervention: Once-daily UMEC/VI 62.5/25 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary endpoint: Pre-dose trough FEV1 on day 169. Sec-
ondary lung function endpoints:Mean TDI focal score at day 168 (week 24); change
from baseline in weighted mean 0-6 hour FEV1 obtained post-dose at day 168 baseline
and day 168. Other outcomes: Change from baseline in the mean Shortness of Breath
With Daily Activities (SOBDA) score for (baseline and week 24)
Reported outcomes: Pre-dose trough FEV1 on treatment day 169, defined as the mean
of FEV1 values obtained 23 h and 24 h after dosing on day 168 (week 24 visit). Secondary
and additional lung function endpoints: weighted mean FEV1 over 0-6 h post-dose on
day 168; trough and 0-6 h weighted mean FEV1 at other visits, serial FEV1 assessments,
time to onset during 0-6 h post-dose on day 1, proportion of participants achieving an
increase in FEV1 of ≥ 12% and ≥ 0.2 L above baseline at any time during 0-6 h post-
dose on day 1, proportion of participants achieving an increase of≥ 0.1 L above baseline
in trough FEV1, peak FEV1 and serial and trough FVC. Serial FEV1 over 0-24 h post-
dose was obtained in a subset of participants to characterise changes in lung function
over the dosing interval
Notes Funding for trial; notable author COIs:The design, concept and conduct of the study
and development of the manuscript was funded by GSK. Both external authors had
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acted as consultants and received research grants from GSK. All other co-authors were
GSK employees
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Simple randomisation was performed cen-
trally through a validated computerised sys-
tem and an interactive voice response sys-
temwas then used to communicate the ran-
domisation to the study team
Allocation concealment (selection bias) Low risk Participants were randomised using an au-
tomated, interactive voice response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masking quadruple (participants, care
provider, investigator, outcome assessor)
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Knowledge of treatment allocation by par-
ticipant or personnel would be unlikely to
influence objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Masking quadruple (participants, care
provider, investigator, outcome assessor)
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition balanced across treatment groups;
ITT analysis performed
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias Low risk None identified.
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Feldman 2012
Methods Study ID and dates performed: NCT01039675; 14 January 2010 to 20 April 2010.
Study design: Multicentre, randomised, placebo-controlled, double-blind, parallel-
group study
Duration of study: Run-in period 5-8 days; 4-week treatment period; 7-day follow-up
Study setting, location, number of centres: 4 centres in the USA.
Key inclusion criteria: Males and females aged ≥ 40 years with an established clinical
history of COPD under the ATS/ERS standards; a history of at least 10 pack-years of
cigarette smoking; a post-albuterol/salbutamol FEV1/FVC≤ 0.70 and a post-albuterol/
salbutamol FEV1 of ≤ 80% of predicted normal values calculated using NHANES III
Key exclusion criteria: Current diagnosis of asthma, alpha1-antitrypsin deficiency; use
of OCS, antibiotics, or had been hospitalised due to exacerbation of COPD or a lower
respiratory tract infection within 3 months prior to screening; abnormal 12-lead ECG
that resulted in an active medical problemor had clinically significant abnormalities from
24-h Holter ECG monitoring at screening; prior evidence of pathological QT waves on
ECG at least 12 months prior to screening that were unchanged at screening were not
exclusionary; use of ICS at a dose > 1000 µg/day of FP or equivalent within 30 days prior
to screening or initiation or termination of ICS use within 30 days prior to screening;
use of long-term oxygen therapy; regular use of short-acting bronchodilators, including
nebulised therapy
Concomitant medications: Permitted concomitant medications: ICS ≤ 1000 µg/
day of FP or equivalent) provided the dose remained constant for 30 days prior to the
screening visit and throughout the study; antibiotics that were not strong inhibitors of
cytochrome P450 3A4 for short-term treatment (≤ 14 days) of acute non-respiratory
tract infections provided that the infection did not meet the criteria for a COPD exac-
erbation.Medications not permitted during study: systemic beta-receptor antagonists
(ophthalmic preparations were allowed); tricyclic antidepressants; monoamine oxidase
inhibitors; anticonvulsants (such as barbiturates); and phenothiazines
Participants N randomised: UMEC/VI 500/25 µg: N = 42; placebo: N = 9.
N analysed, n/N (%): UMEC/VI 500/25 µg: 42/42 (100); placebo: 9/9 (100).
Mean age (range), years: UMEC/VI 500/25 µg: 59.2 (40-83); placebo: 58.7 (42-69).
Gender - male, n/N (%): UMEC/VI 500/25 µg: 24/42 (57.1); placebo: 7/9 (78).
Baseline lung function - mean (SD) post-bronchodilator % predicted FEV1:
UMEC/VI 500/25 µg: 48.37 (15.376); placebo: 50.58 (15.609).
Smoking status, current smoker, n/N (%):UMEC/VI 500/25 µg: 24/42 (57); placebo:
7/9 (78).
Interventions Intervention: Once-daily UMEC/VI 500/25 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Change from baseline in weighted mean pulse rate
over 0 to 6 hours post-dose at day 28 (baseline and day 28). Secondary: change from
baseline in weighted mean pulse rate over 0 to 6 hours post-dose at day 1 and day 14;
change from baseline in maximum and minimum pulse rate 0 to 6 hours post-dose on
days 1, 14, and 28
Reported outcomes: Prespecified primary and secondary outcomes well reported;
Other: weighted mean systolic and diastolic blood pressure 0-6 h post-dose on days 1,
14, and 28; maximum systolic and minimum diastolic blood pressure on days 1, 14,
and 28; 24-h Holter ECG parameters at screening and day 28; maximum QTc with
interval corrected by Fridericia’s method; (during 0-6 h post-dose) on days 1, 14, and
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28 (measured using 12-lead ECG); changes in haematological and clinical chemistry
parameters from baseline on days 14 and 29; incidence of AEs and SAEs throughout the
28-day treatment period and follow-up; incidence of COPD exacerbations; and plasma
concentrations and derived PK Cmax, tmax, AUC for UMEC and VI parameters, and
trough FEV1 on day 29
Notes Funding for trial; notable author COIs: The study was sponsored by GSK and ad-
ministered by Greenville Pharmaceutical Research. All authors received funding from,
or were employees of, GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gener-
ated by the sponsor using a validated com-
puterised system (RandAll)
Allocation concealment (selection bias) Low risk Centralised system used.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigators were blinded
to treatment allocation
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Knowledge of treatment allocation by par-
ticipant or personnel would be unlikely to
influence objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants for subjective outcomes were
the outcome assessors; therefore, low risk
of bias
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Differential withdrawal rates noted be-
tween UMEC/VI and placebo groups;
however, ITT analysis performed
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias High risk Imbalance in baseline characteristics sug-
gested that randomisation was not robust;
limited sample size of placebo group could
also account for imbalance in baseline char-
acteristics
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Methods Study ID and dates performed:NCT01610037 (RADIATE); October 2012-February
2015; abstract only; additional info/data sourced from clinicaltrials.gov
Study design: Multicentre, double-blind (participant & investigator), parallel-group,
placebo- and active-controlled study
Duration of study: 52 weeks.
Study setting, location, number of centres: 116 locations - international.
Key inclusion criteria:Male and female adults aged≥ 40 years; stable COPD according
to GOLD strategy (GOLD 2011); airflow limitation indicated by a post-bronchodilator
FEV1 ≥ 30% and < 80% of the predicted normal, and a post-bronchodilator FEV1/
FVC < 0.70; current or ex-smokers with a smoking history of at least 10 pack years;
participants with an mMRC ≥ grade 2
Key exclusion criteria: History of long QT syndrome or prolonged QTc; COPD ex-
acerbation that required treatment with antibiotics and/or systemic corticosteroids and/
or hospitalisation in the 6 weeks prior to visit 1; type I or uncontrolled type II diabetes;
history of asthma or have concomitant pulmonary disease; paroxysmal (e.g. intermittent)
atrial fibrillation (only patients with persistent atrial fibrillation and controlled with a
rate control strategy for at least six months could be eligible); clinically significant re-
nal, cardiovascular, neurological, endocrine, immunological, psychiatric, gastrointesti-
nal, hepatic, or haematological abnormalities which could interfere with the assessment
of safety
Concomitant medications: Not reported.
Participants N randomised: IND/GLY 110/50 µg: N = 407; placebo: N = 404.
N analysed, n/N (%): IND/GLY 110/50 µg: 407/407 (100); placebo: 403/404 (99.8).
Mean age (SD), years: IND/GLY 110/50 µg: 64.6 (7.89); placebo: 64.9 (7.95).
Gender - male, n/N (%): IND/GLY 110/50 µg: 288/407; placebo: 310/404.
Baseline lung function - post-bronchodilator % predicted FEV1: Not reported.
Smoking status, current smoker, n/N (%): Not reported.
Interventions Intervention: Once-daily IND/GLY 110/50 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary:Number of participants with SAEs during study. Sec-
ondary: Percentage of participants with composite endpoint of all-cause mortality, and
serious cardio- and cerebrovascular events; post hoc analysis: percentage of participants
with composite endpoint of cardiovascular death and MACE change from baseline in
pre-dose FEV1 (days 22, 43, 85, 183, 274, and 364); change from baseline at day 364
in health status as measured by SGRQ for COPD participants; change from baseline at
week 52 in daily, morning, and evening symptom scores; change from baseline at week
52 in percentage of nights with no night-time awakenings; change from baseline at week
52 in percentage of no daytime symptoms; change from baseline at week 52 in percent-
age of days able to perform usual daily activities; change from baseline in 1 hour post-
dose FVC measurements (days 1, 22, 43, 85, 183, 274, and 364); time to premature
discontinuation; change from baseline in 1 hour post-dose FEV1 measurements (days
1, 22, 43, 85, 183, 274, and 364)
Reported outcomes: Prespecified outcome (see above) well reported.
Notes Funding for trial; notable author COIs: The study was funded by Novartis Pharma-
ceuticals.
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided (abstract
only).
Allocation concealment (selection bias) Unclear risk Insufficient information provided (abstract
only).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Clinical trial registry states that ’participant
and investigators’ were blinded to treat-
ment allocation
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Clinical trial registry states that ’participant
and investigators’ were blinded to treat-
ment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants for subjective outcomes were
the outcome assessors; therefore, low risk
of bias
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information provided (abstract
only).
Selective reporting (reporting bias) High risk Abstract did not report key prespecified
outcomes.
Other bias Low risk None identified.
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Methods Study ID and dates performed:NCT01490125 (BLAZE);October 26, 2011 toAugust
29, 2012.
Study design: Randomised, placebo-controlled, multicentre, blinded, double-dummy,
three-period cross-over study
Duration of study: 22 weeks (2-week screening period; 3 X 6-week treatment periods
with 2-week washouts)
Study setting, location, number of centres: 42 centres in 5 countries: Belgium,Canada,
Germany, Spain, and the United Kingdom. “Data were collected in a clinical setting.”
Key inclusion criteria:
Aged≥ 40 years; moderate-to-severe stable COPD (stage II or III according to the 2009
GOLD criteria); were either current smokers or ex-smokers, with a smoking history of
≥ 10 pack-years; post-bronchodilator FEV1 of≥ 30% and < 80% of predicted normal;
post-bronchodilator FEV1/FVC < 0.70 at screening (visit 2, day 14); modified MRC
dyspnoea scale grade of ≥ 2 at visit 2
Key exclusion criteria: Participants were excluded if they: required long-term oxygen
therapy; had a COPD exacerbation (requiring antibiotics, systemic steroids, or hospital-
isation) in the 6 weeks before screening, or between screening and randomisation; had
a respiratory tract infection in the weeks before or during screening; had concomitant
pulmonary disease or had undergone a lung lobectomy, volume reduction or transplanta-
tion; had asthma, eczema, known high IgE levels, blood eosinophil count > 600/mm3 at
screening, or a known positive skin prick test in the previous 5 years; had allergic rhinitis
and used an H1 antagonist or intra-nasal corticosteroids; or if they had α-1 antitrypsin
deficiency
Concomitant medications: Participants were requested not to take short-acting bron-
chodilators in the 6 hours prior to the start of each visit
Participants Note: cross-over study therefore participant data reported for whole cohort.
N randomised: 247.
N analysed: 218.
Mean age (SD), years: 62.8 (8.2).
Gender - male, n/N (%): 173/246 (70.3).
Baseline lung function - mean (SD) post-bronchodilator % predicted FEV1: 56.1
(12.3).
Smoking status, current smoker, n/N (%): 112/246 (45.5).
Interventions Intervention: Once-daily IND/GLY 110/50 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Total Transient Dyspnea Index score after 6 weeks of
treatment (QVA149 versus placebo). Secondary: Total Transient Dyspnea Index score
after 6 weeks of treatment (QVA149 versus tiotropium); standardized FEV1 AUC 5min-
4h after first dose and 6 weeks of treatment (QVA149 vs placebo and tiotropium);
standardised FVC AUC 5 min-4 hrs after first dose and 6 weeks of treatment (QVA149
vs placebo and tiotropium); change from baseline in the Capacity of Daily Living during
theMorning (CDLM) score averaged over 6 weeks of treatment; change from baseline in
the mean daily number of puffs of rescue medication used over the 6 weeks of treatment;
safety
Reported outcomes: All prespecified outcomes (see above) were reported.
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Notes Funding for trial; notable author COIs: The study was funded by Novartis Pharma
AG. Author disclosures not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Investigators used an automated, interac-
tive response technology. Randomisation
numbers generated using this procedure
ensured that treatment assignment was un-
biased and concealed fromparticipants and
investigators
Allocation concealment (selection bias) Low risk Investigators used an automated, interac-
tive response technology. Randomisation
numbers generated using this procedure
ensured that treatment assignment was un-
biased and concealed fromparticipants and
investigators. See supplemental section of
Mahler 2014 for details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants, investigator staff,
personnel performing assessments and data
analysts was maintained. Treatment allo-
cation was blinded by the use of identical
packaging, labelling, schedule of adminis-
tration, appearance, taste, and colour
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Blinding of participants, investigator staff,
personnel performing assessments and data
analysts was maintained. Treatment allo-
cation was blinded by the use of identical
packaging, labelling, schedule of adminis-
tration, appearance, taste, and colour
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants, investigator staff,
personnel performing assessments and data
analysts was maintained. Treatment allo-
cation was blinded by the use of identical
packaging, labelling, schedule of adminis-
tration, appearance, taste, and colour
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Blinding of participants, investigator staff,
personnel performing assessments and data
analysts was maintained. Treatment allo-
cation was blinded by the use of identical
packaging, labelling, schedule of adminis-
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tration, appearance, taste, and colour
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rate was relatively high at ~23%;
however, amodified ITTwas used whereby
attrition rate was effective ~10-15% across
treatment groups
Selective reporting (reporting bias) Low risk Key, prespecified primary and secondary
endpoints were reported as per trial reg-
istry. Slight difference versus prespecified
time points for FEV/FVC noted
Other bias Low risk None identified.
Maltais 2014
Methods Study ID and dates performed: NCT01525615 (TORRACTO); study dates not re-
ported.
Study design: Multicentre, multinational, randomised, double-blind, placebo-con-
trolled, parallel-group trial
Duration of study: 1-week run-in, 12-week treatment period, 3-week follow-up.
Study setting, location, number of centres: 58 centres in 10 countries.
Key inclusion criteria: Aged 40-75 years; clinical diagnosis of COPD and stable airway
obstruction; post-bronchodilator FEV1/FVC < 70% and post-bronchodilator FEV1 <
80% and ≥ 30% predicted normal; current or ex-smokers with a smoking history of >
10 pack-years
Key exclusion criteria: Significant disease other than COPD; a history of asthma, my-
ocardial infarction in the previous year; unstable or life-threatening cardiac arrhythmia,
or hospitalisation for heart failure within the previous year; a recognised contraindication
to exercise; participated in a pulmonary rehabilitation program within the 6 weeks prior
to the screening visit; an exercise limitation other than leg fatigue or exertional dyspnoea
(e.g. arthritis in the leg or morbid obesity)
Concomitant medications: Participants continued with inhaled corticosteroids if taken
at baseline. Open-label salbutamol (albuterol) was provided as rescue medication
throughout the study
Participants N randomised: TIO/OLO 2.5/5 µg: N = 133; TIO/OLO 5/5 µg: N = 139; placebo: N
= 132
N analysed, n/N: TIO/OLO 2.5/5 µg: 129/133 ; TIO/OLO 5/5 µg: n = 135/139;
placebo: n = 121/132
Mean age (SD), years: TIO/OLO 2.5/5 µg: 61.9 (7.3); TIO/OLO 5/5 µg: 63.1 (7.5);
placebo: 60.8 (7.6)
Gender - male, n/N (%): TIO/OLO 2.5/5 µg: 87 (65.4); TIO/OLO 5/5 µg: 95 (68.
3); placebo: 87 (65.9)
Baseline lung function - mean (SD) post-bronchodilator % predicted FEV1: Not
reported.
Smoking status, current smoker, n/N (%): Not reported.
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Interventions Intervention: Once-daily TIO/OLO 2.5/5 µg; once-daily TIO/OLO 5/5 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Adjusted mean endurance time during constant work
rate cycle ergometry after 12 weeks. Secondary: Adjusted mean endurance time during
endurance shuttle walk test after 12 weeks; adjusted mean inspiratory capacity at pre-
exercise after 12 weeks; adjusted mean endurance time during constant work rate cycle
ergometry on day 1, after 6 weeks treatment; adjusted mean inspiratory capacity at
pre-exercise after 1 day and 6 weeks; adjusted mean slope of the intensity of breathing
discomfort on day 1 and after weeks 6 and 12; adjusted mean 1-hour, post-dose FEV1
on day 1, and after 6 and 12 weeks
Reported outcomes: The majority of prespecified outcomes (see above) were reported
although no data provided for FEV1-related outcomes
Notes Funding for trial; notable author COIs: The study was sponsored by Boehringer
Ingelheim Pharma GmbH & Co. KG. All authors except JBGI were either employees
of BI or had received research funding/honoraria from BI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided.
Allocation concealment (selection bias) Unclear risk Insufficient information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided.
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Knowledge of treatment allocation by par-
ticipant or personnel would be unlikely to
influence objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided.
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk According to clinicaltrials.gov results tab,
noncompletion < 20% in each arm (in
fact < 11%) and reasonably balanced across
arms
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Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias Low risk None identified.
Maltais 2014b
Methods Study ID and dates performed: NCT01323660 (Study 417).
Study design: Two multicentre, double-blind, randomised cross-over studies (incom-
plete treatment block)
Duration of study: 12-21-day run-in period; two 12-week treatment periods separated
by a 14-day washout period
Study setting, location, number of centres: 31 centres in 6 countries.
Key inclusion criteria: Current or former smokers; ≤ 40 years of age; smoking history
of ≥ 10 pack-years; clinical diagnosis of moderate-to-severe stable COPD (post-bron-
chodilator FEV1/FVC < 70% and FEV1 ≥ 35% and ≤ 70% predicted); score of ≥ 2
on the mMRC Dyspnoea Scale at visit 1; resting FRC ≥ 120% of predicted (to ensure
participants were hyperinflated, as hyperinflation is associated with exercise intolerance)
Key exclusion criteria: Comorbid conditions or current diagnosis of asthma.
Concomitant medications:All participants were providedwith salbutamol for use on an
‘as-needed’ basis throughout the run-in, washout, and treatment periods. Stable/regular
doses of ICS were permitted
Participants Note: cross-over study therefore participant data reported for whole cohort.
N randomised: N = 349.
N analysed, n/N: 341/349.
Mean age (SD), years: 61.6 (8.3).
Gender - male, n/N (%): 195/348 (56.0).
Baseline lung function - mean (SD) post-bronchodilator % predicted FEV1: 51.3
(9.8).
Smoking status, current smoker, n/N (%): 220/348 (63.2).
Interventions Intervention: Once-daily UMEC/VI 62.5/25 µg; once-daily UMEC/VI 125/25 µg
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Change from baseline in exercise endurance time
post-dose at week 12 of each treatment period; change from baseline in trough FEV1
at week 12 of each treatment period. Secondary: Change from baseline in inspiratory
capacity (trough and 3 hours post-dose) at week 12 of each treatment period; change
from baseline in functional residual capacity (trough and 3 hours post-dose) at week 12
of each treatment period; change from baseline in residual volume (trough and 3 hours
post-dose) at week 12 of each treatment period; change from baseline in 3 hours post-
dose FEV1 at week 12 of each treatment period
Reported outcomes: All prespecified outcomes (see above) plus safety were reported
Notes Funding for trial; notable author COIs: The studies were sponsored by GSK; all
authors were employees of, or had received honoraria/research funding from, GSK
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Maltais 2014b (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Simple randomisation was performed
through a validated computerised system,
then communicated to the study team via
an IVRS
Allocation concealment (selection bias) Low risk Allocation of treatments was controlled by
RAMOS, a telephone-based IRVS
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial registry states that participants and in-
vestigators were blinded to treatment allo-
cation. All six treatments options were ad-
ministered in a ‘double-blind fashion’ via
the same model of inhaler
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Trial registry states that participants and in-
vestigators were blinded to treatment allo-
cation. All six treatments options were ad-
ministered in a ‘double-blind fashion’ via
the same model of inhaler
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants for subjective outcomes were
the outcome assessors; therefore, low risk
of bias
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomes (includ-
ing a co-primary endpoint of exercise tol-
erance time) would be unlikely to be in-
fluenced by knowledge of treatment alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low and comparable attrition in UME/VI
and placebo arms.
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias Low risk None identified.
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Methods Study ID and dates performed: NCT01328444 (Study 418).
Study design: Two multicentre, double-blind, randomised cross-over studies (incom-
plete treatment block)
Duration of study: 12-21-day run-in period; two 12-week treatment periods separated
by a 14-day washout period
Study setting, location, number of centres: 31 centres in 6 countries.
Key inclusion criteria: Current or former smokers; ≤ 40 years of age; smoking history
of ≥ 10 pack-years; clinical diagnosis of moderate-to-severe stable COPD (post-bron-
chodilator FEV1/FVC < 70% and FEV1 ≥ 35% and ≤ 70% predicted); score of ≥ 2
on the mMRC Dyspnoea Scale at visit 1; resting FRC ≥ 120% of predicted (to ensure
participants were hyperinflated, as hyperinflation is associated with exercise intolerance)
Key exclusion criteria: Comorbid conditions or current diagnosis of asthma.
Concomitant medications:All participants were providedwith salbutamol for use on an
‘as-needed’ basis throughout the run-in, washout, and treatment periods. Stable/regular
doses of ICS were permitted
Participants Note: cross-over study therefore participant data reported for whole cohort
N randomised: N = 308.
N analysed, n/N: 307/308.
Mean age (SD), years: 62.6 (7.9).
Gender - male, n/N (%): 168/307 (54.7).
Baseline lung function - mean (SD) post-bronchodilator % predicted FEV1: 51.3
(10.0).
Smoking status, current smoker, n/N (%): 186/307 (60.6).
Interventions Intervention: Once-daily UMEC/VI 62.5/25 µg; once-daily UMEC/VI 125/25 µg
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Change from baseline in exercise endurance time
post-dose at week 12 of each treatment period; change from baseline in trough FEV1
at week 12 of each treatment period. Secondary: Change from baseline in inspiratory
capacity (trough and 3 hours post-dose) at week 12 of each treatment period; change
from baseline in functional residual capacity (trough and 3 hours post-dose) at week 12
of each treatment period; change from baseline in residual volume (trough and 3 hours
post-dose) at week 12 of each treatment period; change from baseline in 3 hours post-
dose FEV1 at week 12 of each treatment period
Reported outcomes: All prespecified outcomes (see above) plus safety were reported
Notes Funding for trial; notable author COIs: The studies were sponsored by GSK; all
authors were employees of, or had received honoraria/research funding from, GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Simple randomisation was performed
through a validated computerised system,
then communicated to the study team via
an IVRS
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Allocation concealment (selection bias) Low risk Allocation of treatments was controlled by
RAMOS, a telephone-based IVRS
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial registry states that participants and in-
vestigators were blinded to treatment allo-
cation. All six treatments options were ad-
ministered in a ‘double-blind fashion’ via
the same model of inhaler
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Trial registry states that participants and in-
vestigators were blinded to treatment allo-
cation. All six treatments options were ad-
ministered in a ‘double-blind fashion’ via
the same model of inhaler
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants for subjective outcomes were
the outcome assessors; therefore, low risk
of bias
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomes (includ-
ing a co-primary endpoint of exercise tol-
erance time) would be unlikely to be in-
fluenced by knowledge of treatment alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low and comparable attrition in UME/VI
and placebo arms.
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias Low risk None identified.
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Methods Study ID and dates performed: NCT00626522; not published (source clinicaltrials.
gov); study completed 2008
Study design: Randomised, 4-week, placebo-controlled, double-blind, 6-arm parallel-
group, dose-finding trial
Duration of study: 4-week treatment period.
Study setting, location, number of centres: 11 sites in 4 countries.
Key inclusion criteria: Aged 40-85 years; clinical diagnosis of stable moderate-to-severe
COPD (GOLD 2006 stages II-III); current or ex-cigarette smoker with a smoking
history of ≥ 10 pack-years; FEV1 at screening measured between 30-45 minutes post-
inhalation of 400 µg of salbutamol was 30% ≤ FEV1 < 80% of the predicted normal
value; FEV1/FVC at screening measured between 30- 45 minutes post inhalation of 400
µg of salbutamol was < 70%
Key exclusion criteria:History or current diagnosis of asthma, allergic rhinitis or atopy,
or exercise-induced bronchospasm; clinically significant respiratory conditions at the
time of screening visit; hospitalisation due to COPD exacerbation within 3months prior
to screening; signs of COPD exacerbation or respiratory infection up to 6 weeks prior
to screening visit; clinically significant cardiovascular conditions
Concomitant medications: Not reported.
Participants N randomised: ACL/FOR 200/6 µg: n = 121; ACL/FOR 200/12 µg: n = 120; ACL/
FOR 200/18 µg: n = 125; placebo: n = 59
Nanalysed: ACL/FOR200/6 µg: 121/121 (100); ACL/FOR200/12 µg: 120/120 (100)
; ACL/FOR 200/18 µg: 125/125 (100); placebo: 59/59 (100)
Mean age (SD), years: ACL/FOR 200/6 µg: 62.9 (9.0); ACL/FOR 200/12 µg: 63.6 (8.
9); ACL/FOR 200/18 µg: 63.9 (8.1); placebo: 60.7 (7.8)
Gender - male, n/N: ACL/FOR 200/6 µg: 91/121; ACL/FOR 200/12 µg: 98/120;
ACL/FOR 200/18 µg: 96/125; placebo: 44/59
Baseline lung function - post-bronchodilator % predicted FEV1: Not reported.
Smoking status, current smoker, n/N (%): Not reported.
Interventions Intervention:Once-daily ACL/FOR 200/6 µg; once-daily ACL/FOR 200/12 µg; once-
daily ACL/FOR 200/18 µg
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Change from baseline in normalised FEV1 AUC for
0-12 hr at week 4. Secondary: Change from baseline in trough FEV1 at week 4; change
from baseline in peak FEV1 at week 4; change from baseline in normalised FEV1 AUC
0-3 hours at week 4; change from baseline in normalised FEV1 AUC 0-6 hours at week
4
Reported outcomes: All of the prespecified outcomes (see above) plus safety were re-
ported on the clinicaltrials.gov site
Notes Funding for trial; notable author COIs: The study was sponsored by AstraZeneca.
Risk of bias
Bias Authors’ judgement Support for judgement
68Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic
obstructive pulmonary disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT00626522 (Continued)
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided (trial
registry only).
Allocation concealment (selection bias) Unclear risk Insufficient information provided (trial
registry only).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigators blinded.
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Participants and investigators blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants for subjective outcomes were
the outcome assessors; therefore, low risk
of bias
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were low and balanced be-
tween treatment groups
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias Low risk None identified.
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Methods Study ID and dates performed: NCT02275052
Study design: A multicenter, randomised, double-blind, placebo-controlled, 2-period,
complete block design cross-over study
Duration of study: 2 x 12-week treatment periods with washout of 12-17 days. Run in
period 12-25 days. Total duration approximately 30 weeks including follow up
Study setting, location, number of centres: United States of America.
Key inclusion criteria: Aged ≥ 40 years; diagnosis of COPD (ATS/ERS); current or
former cigarette smokers with a history of cigarette smoking of ≥ 10 pack-years; pre-
and post-albuterol FEV1/FVC < 0.70 and a post-albuterol FEV1 of ≥ 30% and≤ 70%
of predicted normal value; dyspnoea score of≥ 2 on the mMRC scale at visit 1; a resting
FRC of ≥ 120% of predicted normal FRC at visit 1
Key exclusion criteria: Pregnancy; current diagnosis of asthma; other respiratory disor-
ders; known alpha-1 antitrypsin deficiency; active lung infections (such as tuberculosis)
, and lung cancer in remission for < 5 years
Concomitant medications: Permitted: All participants were provided with albuterol
for use on an ’as needed’ basis throughout the run-in, washout, and study treatment
periods while on investigational product. Use of the following medications according to
the following defined time intervals prior to visit 1: Depot corticosteroids (12 weeks),
systemic, oral or parenteral corticosteroids (Intra-articular and epidural corticosteroid in-
jections were permitted) (6 weeks), antibiotics (for lower respiratory tract infection and/
or COPD exacerbation) (6 weeks), long-acting beta agonist (LABA)/inhaled corticos-
teroid (ICS) combination products if LABA/ICS therapy was discontinued completely
(30 days), LABA/ICS combination products only if discontinuing LABA therapy and
switching to ICS monotherapy (dose of ICS that is switched to must not exceed 1000
µg of fluticasone propionate or equivalent) (48 hours for the salmeterol or formoterol
component, 14 days for the vilanterol component), use of ICS at a dose > 1000 µg/day
of fluticasone propionate or equivalent (use of ICS was permitted provided the dose did
not exceed 1000µg of fluticasone propionate or equivalent; ICS use not to be initiated or
discontinued within 30 days prior to visit 1 except for participants on LABA/ICS therapy
who may discontinue LABA/ICS therapy as indicated and switch to ICS monotherapy)
(30 days), initiation or discontinuation of ICS use (30 days), PDE4 inhibitor (roflumi-
last) (14 days), Inhaled LABA: salmeterol, formoterol (48 hours); olodaterol, indacaterol
(14 days), LAMA (tiotropium, aclidinium, glycopyrronium, umeclidinium) (7 days)
, LABA/LAMA combination products (whichever mono component had the longest
washout), theophyllines (48 hours), oral beta2-agonists (long-acting (48 hours), short-
acting (12 hours), inhaled SABA (study provided prn albuterol was permitted during
the study, except in the 4-hour period prior to spirometry testing) (4 hours), inhaled
short-acting anticholinergics (permitted during the run-in period between visits 1 and
4 and washout period between visits 7 and 9. Restricted/non-permitted: Participants
must discontinue use of short-acting anticholinergics at least 4 hours before visit 4 and
visit 9. Participants should not use short acting anticholinergics during the double-blind
treatment periods (4 hours), inhaled short-acting anticholinergic/SABA combination
products (4 hours), and any other investigational medication (30 days or within 5 drug
half-lives (whichever was longer))
Participants Note: cross-over study therefore participant data reported for whole cohort.
N randomised: N = 99.
N analysed, n/N: UMEC/VI 62.5/25 µg: 93/99; placebo: 90/99.
Mean age (SD), years: 60.7 (9.47).
Gender - male, n/N (%): 104/198 (52.5).
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Baseline lung function - post-bronchodilator % predicted FEV1: Not reported.
Smoking status, current smoker, n/N (%): Not reported.
Interventions Intervention: Once-daily UMEC/VI 62.5/25 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary outcome: change from baseline in exercise endurance
time post-dose at week 12 of each treatment period. Secondary outcome: change from
baseline in trough FEV1 at week 12 of each treatment period; change from baseline in
FRC 3 hours post-dose at week 12 of each treatment period; change from baseline in IC
3 hours post-dose at week 12 of each treatment period
Reported outcomes: All of the prespecified outcomes (see above) plus safety were re-
ported on the clinicaltrials.gov site
Notes Funding for trial; notable author COIs: Study sponsored by GlaxoSmithKline.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided (trial
registry only).
Allocation concealment (selection bias) Unclear risk Insufficient information provided (trial
registry only).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigators were blinded
to treatment allocation
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Participants and investigators were blinded
to treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants for subjective outcomes were
the outcome assessors; therefore, low risk
of bias
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rate < 20% and balanced between
treatment arms.
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
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Other bias Low risk None identified.
O’Donnell 2015a
Methods Study ID and dates performed: NCT01533922 (MORACTO-1); study dates not
stated.
Study design: Double-blind, 6-week incomplete cross-over study.
Duration of study: 38-40 weeks, including a 2-4 week run-in period.
Study setting, location, number of centres: 82 investigational sites in 13 countries.
Key inclusion criteria: Aged 40-75 years; post-bronchodilator (400 µg salbutamol)
FEV1/FVC < 70%; post-bronchodilator FEV1 ≥ 30% and < 80% of predicted normal
(GOLD 2-3); current or ex-smokers with a smoking history of > 10 pack-years
Key exclusion criteria: Significant disease other than COPD; unstable or life-threaten-
ing cardiac arrhythmia; hospitalisation for heart failure or myocardial infarction within
the past year; regular use of daytime oxygen therapy for > 1 h per day; history of asthma
and contraindications to exercise as per the ERS guidelines
Concomitant medications: Permitted: Participants continued with inhaled corticos-
teroids if taken at baseline; open-label salbutamol (albuterol) was provided as rescue
medication throughout the study. Restricted/not permitted: LABA or LAMA (other
than study medication) during the baseline, treatment, and washout periods; short-act-
ing muscarinic antagonists during the treatment periods (permitted only during baseline
and washout periods, with an 8-h washout prior to assessments)
Participants Note: cross-over study therefore participant data reported forwhole cohort; baseline
characteristics and participant flow reported for combined studies (MORACTO-1
and MORACTO-2).
N randomised: N = 586.
N analysed, n/N: TIO/OLO 2.5/5 µg: 424/442; TIO/OLO 5/5µg: 428/450; placebo:
413/438
Mean age (SD), years: 61.7 (7.7).
Gender - male, n/N (%): 417/586 (71.2).
Baseline lung function - mean (SD) post-bronchodilator% predicted FEV1: 58 (13)
.
Smoking status, current smoker, n/N (%): 229/586 (39.1).
Interventions Intervention: Once-daily TIO/OLO 2.5/5 µg; once-daily TIO/OLO 5/5 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Inspiratory capacity at rest immediately before con-
stant work rate cycle ergometry (assessed at 6 weeks); endurance time during constant
work rate cycle ergometry. Secondary: Slope of the intensity of breathing discomfort
during constant work rate cycle ergometry (assessed at 6 weeks); 1-hour post-dose FEV1
(assessed at 6 weeks)
Reported outcomes: All prespecified outcomes (see above) plus FVC and safety and
tolerability
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Notes Funding for trial; notable author COIs: This work was funded by BI Pharma GmbH
& Co. All authors were either employees of BI or had received research funding or
honoraria from BI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided.
Allocation concealment (selection bias) Unclear risk Insufficient information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided.
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Knowledge of treatment allocation by par-
ticipant or personnel would be unlikely to
influence objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided.
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar attrition with similar reasons for
combined treatment arm and placebo arm;
discontinuation rates < 5%
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias Low risk None identified.
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Methods Study ID and dates performed: NCT01533935 (MORACTO-2); study dates not
stated.
Study design: Double-blind, 6-week incomplete cross-over study.
Duration of study: 38-40 weeks, including a 2-4 week run-in period.
Study setting, location, number of centres: 82 investigational sites in 13 countries.
Key inclusion criteria: Aged 40-75 years; post-bronchodilator (400 µg salbutamol)
FEV1/FVC < 70%; post-bronchodilator FEV1 ≥ 30% and < 80% of predicted normal
(GOLD 2-3); current or ex-smokers with a smoking history of > 10 pack-years
Key exclusion criteria: Significant disease other than COPD; unstable or life-threaten-
ing cardiac arrhythmia; hospitalisation for heart failure or myocardial infarction within
the past year; regular use of daytime oxygen therapy for > 1 h per day; history of asthma
and contraindications to exercise as per the ERS guidelines
Concomitant medications: Permitted: Participants continued with inhaled corticos-
teroids if taken at baseline; open-label salbutamol (albuterol) was provided as rescue
medication throughout the study. Restricted/not permitted: LABA or LAMA (other
than study medication) during the baseline, treatment, and washout periods; short-act-
ing muscarinic antagonists during the treatment periods (permitted only during baseline
and washout periods, with an 8-h washout prior to assessments)
Participants Note: cross-over study therefore participant data reported forwhole cohort; baseline
characteristics and participant flow reported for combined studies (MORACTO-1
and MORACTO-2).
N randomised: N = 586.
N analysed, n/N: TIO/OLO 2.5/5 µg: 424/442; TIO/OLO 5/5µg: 28/450; placebo:
413/438
Mean age (SD), years: 61.7 (7.7).
Gender - male, n/N (%): 417/586 (71.2).
Baseline lung function - mean (SD) post-bronchodilator% predicted FEV1: 58 (13)
.
Smoking status, current smoker, n/N (%): 229/586 (39.1).
Interventions Intervention: Once-daily TIO/OLO 2.5/5 µg; once-daily TIO/OLO 5/5µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Inspiratory capacity at rest immediately before con-
stant work rate cycle ergometry (assessed at 6 weeks); endurance time during constant
work rate cycle ergometry. Secondary: Slope of the intensity of breathing discomfort
during constant work rate cycle ergometry (assessed at 6 weeks); 1-hour post-dose FEV1
(assessed at 6 weeks)
Reported outcomes: All prespecified outcomes (see above) plus FVC and safety and
tolerability
Notes Funding for trial; notable author COIs: This work was funded by BI Pharma GmbH
& Co. All authors were either employees of BI or had received research funding or
honoraria from BI
Risk of bias
Bias Authors’ judgement Support for judgement
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O’Donnell 2015b (Continued)
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided.
Allocation concealment (selection bias) Unclear risk Insufficient information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided.
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Knowledge of treatment allocation by par-
ticipant or personnel would be unlikely to
influence objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided.
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar attrition with similar reasons for
combined treatment arm and placebo arm;
discontinuation rates < 5%
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias Low risk None identified.
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Siler 2016
Methods Study ID and dates performed: NCT02152605; September 2014 to March 2015.
Study design: Multicentre, randomised, double-blind, parallel-group, placebo-con-
trolled study
Duration of study: 7-14 day run-in period; 12-week treatment period.
Study setting, location, number of centres: 55 centres in Bulgaria, Germany, Hungary,
Romania, Russian Federation, Ukraine, and US
Key inclusion criteria:≥ 40 years of age; diagnosis of COPD; current or prior history of
≥ 10 pack-years of cigarette smoking at screening; a pre- and post-albuterol (salbutamol)
FEV1/FVC < 0.70 and a post-albuterol FEV1 ≤ 70% of predicted normal values at
screening (based on NHANES III reference equations; a score ≥ 2 on the mMRC
Dyspnoea Scale at screening
Key exclusion criteria: Current diagnosis of asthma or other known respiratory con-
ditions (α1-antitrypsin deficiency, active tuberculosis, lung cancer, bronchiectasis, sar-
coidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases, or other active
pulmonary diseases); hospitalisation for COPD or pneumonia within 12 weeks prior
to visit 1; lung volume reduction surgery within the 12 months prior to visit 1; use of
long-term oxygen therapy (prescribed for > 12 h/day); severe hepatic impairment; any
rapidly progressing disease or immediate life-threatening illness (e.g. cancer); any condi-
tion that was likely to affect respiratory function (e.g. neurological condition); abnormal,
clinically significant electrocardiogram finding at screening (atrial fibrillation with rapid
ventricular rate > 120 bpm; sustained or nonsustained ventricular tachycardia; second-
degree heart block Mobitz type II, and third-degree heart block (unless pacemaker or
defibrillator had been inserted))
Concomitant medications: Use of study-provided albuterol was permitted, except in
the 4-hour period prior to spirometry testing. Excluded medications prior to visit 1: de-
pot corticosteroids; systemic, oral or parenteral corticosteroids; ICS/LABA combination
products; ICS at a dose > 1000 µg/day of FP or equivalent; initiation or discontinua-
tion of ICS use; PDE4 inhibitors; LAMAs, inhaled LABAs, LABA/LAMA combination
products; theophyllines; oral beta2-agonists; inhaled SABA or inhaled short-acting an-
ticholinergics, or any combination of the two
Participants N randomised: UMEC/VI 62.5/25 µg: n = 249; placebo: n = 249.
N analysed, n/N: UMEC/VI 62.5/25 µg: 248/249; placebo: 248/249.
Mean age (SD), years: UMEC/VI 62.5/25 µg: 64.1 (8.70); placebo: 62.6 (8.23).
Gender - male, n/N (%):UMEC/VI 62.5/25 µg: 144/248 (58); placebo: 149/248 (60)
.
Baseline lung function - mean (SD) post-bronchodilator % predicted FEV1:
UMEC/VI 62.5/25 µg: 46.5 (12.81); placebo: 48.4 (14.06).
Smoking status, current smoker, n/N (%): UMEC/VI 62.5/25 µg: 137/248 (55);
placebo: 129/248 (52).
Interventions Intervention: Once-daily UMEC/VI 62.5/25 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Change from baseline in mean SGRQ total score
at day 84. Secondary: Change from baseline in trough FEV1 at day 84; change from
baseline in mean number of puffs of rescue medication per day used over weeks 1-12
Reported outcomes: plus the proportion of SGRQ responders at days 28, 56, and 84;
SGRQ total score at days 28 and 56 (SGRQ responders were defined as having a total
score ≥ 4 units below baseline); percentage of rescue-free days; trough FEV1 at days 28
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and 56; trough FVC at days 28, 56, and 84; safety
Notes Funding for trial; notable author COIs: The study was funded by GSK. Lead author
had received research funding from GSK. All other authors were employees of GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised IRVS systemused for randomi-
sation.
Allocation concealment (selection bias) Low risk Centralised IRVS systemused for randomi-
sation.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigators were blinded
to treatment (see clinicaltrial.gov)
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Participants and investigators were blinded
to treatment (see clinicaltrial.gov)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided.
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar loss in both arms (treatment and
placebo) for similar reasons and loss < 10%
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias High risk Greater proportion of participants with
GOLD category D in the active treatment
group; favoured placebo and underestima-
tion of treatment effect
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Singh 2016a
Methods Study ID and dates performed: NCT01964352 (OTEMTO 1).
Study design: A multinational, double-blind, parallel-group, placebo-controlled study
Duration of study: 2-week run-in period; 12-week treatment period; 3-week follow-up
Study setting, location, number of centres: Not stated.
Key inclusion criteria: Participants aged ≥ 40 years with moderate to severe COPD
(GOLD 2-3); post-bronchodilator FEV1 ≥ 30% and < 80% of predicted normal),
FEV1/FVC < 70% predicted and a smoking history of > 10 pack-years
Key exclusion criteria: A history of asthma, another significant disease, COPD exacer-
bation or symptoms of lower respiratory tract infection within the previous 3 months;
unstable or life-threatening cardiac arrhythmia, hospitalisation for heart failure within
the past year; a history of myocardial infarction within 1 year of screening; a history of
life-threatening pulmonary obstruction
Concomitant medications: Participants were allowed to continue their ICS therapy (if
they were on a stable dose for 6 weeks prior to screening). LAMAs or LABAs other than
study medication were prohibited; short-acting muscarinic antagonists were permitted
only during the screening period. Open-label salbutamol was provided as rescue medi-
cation for use throughout the study
Participants N randomised: TIO/OLO 2.5/5 µg: n = 202; TIO/OLO 5/5 µg: n = 204; placebo: n
= 204
N analysed, n/N (%): TIO/OLO 2.5/5 µg: 196/202 (97.0); TIO/OLO 5/5 µg: 195/
204 (96.1); placebo: 178/204 (87.3)
Mean age (SD), years: TIO/OLO 2.5/5 µg: 64.7 (8.2); TIO/OLO 5/5 µg: 64.7 (8.9);
placebo: 65.1 (8.3)
Gender - male, n/N (%): TIO/OLO 2.5/5 µg: 116 (57.4); TIO/OLO 5/5 µg: 114 (56.
2); placebo: 127 (62.3)
Baseline lung function - mean (SD) post-bronchodilator % predicted FEV1: TIO/
OLO 2.5/5 µg: 55.5 (13.7); TIO/OLO 5/5 µg: 54.9 (12.0); placebo: 56.3 (12.8)
Smoking status, current smoker, n/N (%): TIO/OLO 2.5/5 µg: 98/202 (48.5); TIO/
OLO 5/5 µg: 111/203 (54.7); placebo: 88/204 (43.1)
Interventions Intervention: Once-daily TIO/OLO 2.5/5 µg; once-daily TIO/OLO 5/5 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: FEV1 AUC 0-3 h response at 12 weeks; trough FEV1
response at 12 weeks; SGRQ total score at 12 weeks. Secondary: trough FVC response
(change from baseline) at 12 weeks; TDI focal score at 12 weeks; FVC AUC 0-3 h
response (change from baseline) at 12 weeks
Reported outcomes: All prespecified outcomes (see above) were reported.
Notes Funding for trial; notable author COIs: This study was funded by Boehringer In-
gelheim Pharma GmbH & Co. KG. Seven of nine authors were employees of, or had
received funding/honoraria from, BI. Two authors disclosed no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Insufficient information provided.
Allocation concealment (selection bias) Unclear risk Insufficient information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided.
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Knowledge of treatment allocation by par-
ticipant or personnel would be unlikely to
influence objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided.
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rate was < 15% in placebo and
combined LABA/LAMA arms
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias Low risk None identified. Note slightly higher rates
of discontinuation in placebo arm - likely
accounted for due to the most severely ill
participants dropping out. Potential posi-
tive placebo treatment effect not observed
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Methods Study ID and dates performed: NCT02006732 (OTEMTO 2).
Study design: One of two multinational, double-blind, parallel-group, placebo-con-
trolled studies
Duration of study: 2-week run-in period; 12-week treatment period; 3-week follow-up
Study setting, location, number of centres: Not stated.
Key inclusion criteria: Participants aged ≥ 40 years with moderate to severe COPD
(GOLD 2-3); post-bronchodilator FEV1 ≥ 30% and < 80% of predicted normal),
FEV1/FVC < 70% predicted and a smoking history of > 10 pack-years
Key exclusion criteria: A history of asthma, another significant disease, COPD exacer-
bation or symptoms of lower respiratory tract infection within the previous 3 months;
unstable or life-threatening cardiac arrhythmia, hospitalisation for heart failure within
the past year; a history of myocardial infarction within 1 year of screening; a history of
life-threatening pulmonary obstruction
Concomitant medications: Participants were allowed to continue their ICS therapy (if
they were on a stable dose for 6 weeks prior to screening). LAMAs or LABAs other than
study medication were prohibited; short-acting muscarinic antagonists were permitted
only during the screening period. Open-label salbutamol was provided as rescue medi-
cation for use throughout the study
Participants N randomised: TIO/OLO 2.5/5 µg: n = 202; TIO/OLO 5/5 µg: n = 202; placebo: n
= 202
N analysed, n/N: TIO/OLO 2.5/5 µg: 193/202; TIO/OLO 5/5 µg: 198/202; placebo:
182/202
Mean age (SD), years: TIO/OLO 2.5/5 µg: 64.4 (8.6); TIO/OLO 5/5 µg: 65.2 (8.5);
placebo: 64.0 (8.3)
Gender - male, n/N (%): TIO/OLO 2.5/5 µg: 126 (62.4); TIO/OLO 5/5 µg: 133 (65.
8); placebo: 117 (57.9)
Baseline lung function - mean (SD) post-bronchodilator % predicted FEV1: TIO/
OLO 2.5/5 µg: 54.5 (12.7); TIO/OLO 5/5 µg: 54.8 (12.8); placebo: 54.3 (13.4)
Smoking status, current smoker, n/N (%): TIO/OLO 2.5/5 µg: 90/202 (44.6) ; TIO/
OLO 5/5 µg: 92/202 (45.5); placebo: 95/202 (47.0)
Interventions Intervention: Once-daily TIO/OLO 2.5/5 µg; once-daily TIO/OLO 5/5 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: FEV1 AUC 0-3 h response at 12 weeks; trough FEV1
response at 12 weeks; SGRQ total score at 12 weeks. Secondary: trough FVC response
(change from baseline) at 12 weeks; TDI focal score at 12 weeks; FVC AUC 0-3 h
response (change from baseline) at 12 weeks
Reported outcomes: All prespecified outcomes (see above) were reported.
Notes Funding for trial; notable author COIs: This study was funded by Boehringer In-
gelheim Pharma GmbH & Co. KG. Seven of nine authors were employees of, or had
received funding/honoraria from, BI. Two authors disclosed no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Insufficient information provided.
Allocation concealment (selection bias) Unclear risk Insufficient information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided.
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Knowledge of treatment allocation by par-
ticipant or personnel would be unlikely to
influence objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided.
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rate was < 15% in placebo and
combined LABA/LAMA arms
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias Low risk None identified. Note slightly higher rates
of discontinuation in placebo arm - likely
accounted for due to the most severely ill
participants dropping out. Potential posi-
tive placebo treatment effect not observed
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Methods Study ID and dates performed: NCT02085161; PHYSACTO; dates not reported.
Study design:Randomised, partially double-blinded, placebo-controlled, parallel-group
trial
Duration of study: 19 weeks (4-week run-in; 12-week treatment period; 3-week follow-
up)
Study setting, location, number of centres: 34 sites in Australia, New Zealand, USA,
Canada, Europe (17 academic centres, 15 secondary care and 5 primary care centres)
Key inclusion criteria:COPD; aged≥ 40 years and≤ 75 years; smoking history of > 10
pack-years; post-bronchodilator FEV1≥ 30% and < 80% of predicted normal (GOLD
2-3) and no acute exacerbations in the month prior to the study; post-bronchodilator
FEV1/FVC < 70%
Key exclusion criteria: Significant disease other than COPD; history of asthma; clini-
cally relevant abnormal baseline haematology, blood chemistry or urinalysis; conditions
excluding participants from exercise
Concomitant medications: Not reported.
Participants N randomised: TIO/OLO 5/5 µg: n = 76; placebo: n = 76.
N analysed, n/N: TIO/OLO 5/5 µg: 72/76; placebo: 65/76.
Mean age (SD), years: TIO/OLO 5/5 µg: 65.0 (6.9); placebo: 64.4 (6.6).
Gender - male, n/N (%): TIO/OLO 5/5 µg: 48/76 (63.2); placebo: 52/75 (69.3).
Baseline lung function - post-bronchodilator % predicted FEV1: Not reported.
Smoking status, current smoker, n/N (%): Not reported.
Interventions Intervention: Once-daily TIO/OLO 5/5 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Endurance time during endurance shuttle walk test
(to symptom limitation) after 8 weeks. Secondary: average daily walking time measured
by the activity monitor in the week prior to week 12; average daily walking intensity
measured by the activity monitor in the week prior to 12 weeks of treatment; perceived
difficulties as evaluated with functional performance inventory-short form (FPI-SF) total
score at week 12; endurance time during endurance shuttle walk test (to symptom
limitation) after 12 weeks; one-hour, post-dose FEV1 after 8 weeks of treatment; one-
hour, post-dose FVC after 8 weeks of treatment; resting inspiratory capacity measured
at 1.5 hours post-dose after 8 weeks of treatment
Reported outcomes: Prespecified outcomes (clinicaltrials.gov) were well reported
Notes Funding for trial; notable author COIs: Study sponsored by BI. Authors had received
funding or honoraria from BI, or were employees of BI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Randomisation is performed using a
pseudo-random number generator and
block randomisation is used to achieve bal-
anced allocation”
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Allocation concealment (selection bias) Low risk Web-based and telephone-based response
system used.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Partially double-blind’ as it was not pos-
sible to blind participants and person-
nel to the receipt of exercise training
or behavioural modifications. However;
the groups of interest (TIO/OLO and
placebo) received treatments in double-
blind fashion (participants and personnel
were blinded)
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Knowledge of treatment allocation by par-
ticipant or personnel would be unlikely to
influence objective outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants for subjective outcomes were
the outcome assessors; therefore, low risk
of bias
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rate was < 20% and the difference
in attrition rates between relevant treat-
ment groups was < 10%
Selective reporting (reporting bias) Low risk Data presented on clinicaltrials.gov website
appeared in line with protocol
Other bias Low risk None identified.
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Methods Study ID and dates performed: ; NCT01996319 (MOVE); study dates not reported.
Study design: Randomised, placebo-controlled, double-blind, multicentre, cross-over
study
Duration of study: Flexible run-in period (duration dependent on COPD medication
at baseline; two 21-day treatment periods separated by a 14-day washout
Study setting, location, number of centres: Multicentre, randomised, double-blind,
placebo-controlled cross-over study, conducted at 30 secondary care (pulmonology) prac-
tices in Germany
Key inclusion criteria: Stable COPD according to the current GOLD guidelines
(GOLD 2013); current or ex-smokers; smoking history of ≥ 10 pack years; airflow lim-
itation indicated by a post-bronchodilator FEV1 ≥ 40% and < 80% of the predicted
normal, and a post-bronchodilator FEV1/FVC < 0.70
Key exclusion criteria: Concomitant pulmonary disease, history of asthma, onset of
respiratory symptoms prior to age 40 years, blood eosinophil count > 600/mm3 during
run-in, or a clinically significant abnormality that could interfere with the assessment of
efficacy or safety of the study; COPD exacerbation in the 6 weeks prior to screening or
during the run-in period; respiratory tract infection within 4 weeks prior to screening
or during the run-in period
Concomitant medications: The following COPDmedication was prohibited from the
indicated time prior to visit 2 and for the duration of the study: LAMAs (7 days); LABAs
(48 h; 7 days for indacaterol); xanthines and oral phosphodiesterase IV inhibitors (7 days)
. ICS were permitted, at a stable dose throughout the study (participants on a LABA/ICS
combination were to be switched to the nearest equivalent dose of ICS monotherapy at
least 48 h prior to visit 2)
Participants Note: cross-over study therefore participant data reported for whole cohort.
N randomised: N = 194.
N analysed: N = 194.
Mean age (SD), years: 62.8 (7.9).
Gender - male, n/N (%): 127/194 (65.5).
Baseline lung function - mean (SD), post-bronchodilator % predicted FEV1: 61.6
(10.7).
Smoking status, current smoker, n/N (%): 110/194 (56.7).
Interventions Intervention: Once-daily IND/GLY 110/50 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Change from baseline in peak IC (IND/GLY ver-
sus placebo); change from baseline in average physical activity level (IND/GLY versus
placebo). Secondary: Average number of steps per day; change in the duration of at least
moderate activity per day; change from baseline in peak IC; change from baseline in the
trough IC; peak FEV1 at day 1; trough FEV1 comparison after 22 days
Reported outcomes: Prespecified outcomes (clinicaltrials.gov) were well reported
Notes Funding for trial; notable author COIs: This study was funded by Novartis Pharma.
All authors were employees of Novartis, or received research funding/honoraria from
Novartis
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The random number sequence was gener-
ated by the sponsor using a validated auto-
mated system
Allocation concealment (selection bias) Unclear risk Insufficient information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, staff, persons performing the
assessments, sponsor, and data analysts
were blinded to treatment
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Participants, staff, persons performing the
assessments, sponsor, and data analysts
were blinded to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Persons performing the assessments were
blinded to treatment
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Persons performing the assessments were
blinded to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants received at
least one dose of allocated treatment and
were included in the full analysis set
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias Low risk Cross-over design may not be appropriate
for a study that examines physical activ-
ity end points, which require a change in
lifestyle - washout periods may be insuffi-
cient.However, physical activity end points
were not included in the presentmeta-anal-
yses
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Methods Study ID and dates performed: NCT01636713; dates not reported.
Study design: Multicentre, randomised, double-blind, placebo-controlled, parallel-
group study
Duration of study: 7-14 day run-in; 24-week treatment period.
Study setting, location, number of centres: People’s Republic of China, Philippines,
South Korea, Taiwan, Thailand
Key inclusion criteria: Aged ≥ 40 years at screening; established clinical history of
COPD (ATS/ERS criteria); current or former smokers with a smoking history ≥ 10
pack-years; post-albuterol FEV1/FVC < 0.70 and a post-albuterol FEV1 ≤ 70% of
predicted normal values (NHANES III reference equations at visit 1); dyspnoea score of
≥ 2 on the mMRC Dyspnea Scale at screening
Key exclusion criteria: Current diagnosis of asthma or any other known respiratory
disorder, including α1-anti-trypsin deficiency or active lung infection, e.g. tuberculosis,
lung cancer, clinically significant bronchiectasis, pulmonary hypertension, sarcoidosis,
or interstitial lung disease; previous history or current evidence of clinically significant
or uncontrolled cardiovascular, neurological, psychiatric, renal, hepatic, immunological,
endocrine, or haematological abnormalities
Concomitant medications: Permitted: Supplemental albuterol as rescue medication;
ICS < 1000 µg/day of FP or equivalent; ICS not initiated or discontinued within 30
days prior to study entry
Participants N randomised: UMEC/VI 62.5/25 µg: n = 194; UMEC/VI 125/25 µg: n = 193;
placebo: n = 193
N analysed, n/N (100):UMEC/VI 62.5/25 µg: 194/194 (100); UMEC/VI 125/25 µg:
193/193 (100); placebo: 193/193 (100)
Mean age (SD), years: UMEC/VI 62.5/25 µg: 64.0 (8.71); UMEC/VI 125/25 µg: 63.
7 (8.26); placebo: 64.3 (8.78)
Gender - male, n (%): UMEC/VI 62.5/25 µg: 183 (94); UMEC/VI 125/25 µg: 182
(94); placebo: 177 (92)
Baseline lung function - mean (SD) post-bronchodilator FEV1, L:UMEC/VI 62.5/
25 µg: 1.131 (0.3965); UMEC/VI 125/25 µg: 1.195 (0.3889); placebo: 1.168 (0.3708)
Smoking status, current smoker, n/N (%): UMEC/VI 62.5/25 µg: 56/194 (29);
UMEC/VI 125/25 µg: 48/193 (25); placebo: 65/193 (34)
Interventions Intervention: Once-daily UMEC/VI 62.5/25 µg; once-daily UMEC/VI 125/25 µg
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary: Change from baseline in trough FEV1 on day 169
(week 24). Secondary: Transition Dyspnea Index (TDI) Focal Score at day 168 (week
24); change from baseline weighted mean 0-6 hour FEV1 obtained post-dose at day 1
Reported outcomes: Prespecified outcomes (clinicaltrials.gov) were well reported, plus
trough FEV1 at other time points; serial FEV1 over 0-6 hours post-dose at day 1; the
proportion of participants achieving an increase in FEV1 of ≥ 12% and ≥ 0.200 L
above baseline at any time 0-6 hours post-dose on day 1; the proportion of participants
achieving an increase of ≥ 0.100 L above baseline in trough FEV1; and trough and
serial FVC and time to onset 0-6 hours post-dose at day 1; TDI focal score recorded at
other time points; proportion of TDI responders (a responder to TDI was defined as a
participant who reported a TDI score of ≥ 1 unit); rescue-albuterol use (percentage of
rescue-free days and puffs/day) and time to first COPD exacerbation (defined as an acute
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worsening of symptoms of COPD requiring the use of rescue albuterol or any treatment
beyond study medication); safety
Notes Funding for trial; notable author COIs: GSK funded this study. Lead author has
received lecture fees from GSK. 3 of 4 co-authors are employees of GSK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation schedule was generated
by GSK using the validated computerised
system RandAll version 2.5
Allocation concealment (selection bias) Low risk Used the sponsors formal system for ran-
domisation so although concealment not
specifically stated, it seems likely that this
was done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigators were blinded
to treatment allocation
Blinding of participants and personnel (ob-
jective outcomes - performance bias)
Objective outcomes
Low risk Participants and investigators were blinded
to treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants for subjective outcomes were
the outcome assessors; therefore, low risk
of bias
Blinding of outcome assessment (objective
outcomes - detection bias)
All outcomes
Low risk Assessment of objective outcomeswould be
unlikely to be influenced by knowledge of
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition based on completion rates < 20%
across arms. Data reported for ITT popu-
lation
Selective reporting (reporting bias) Low risk Prespecified outcomes (clinicaltrials.gov)
were well reported
Other bias High risk Higher proportion of participants with
GOLD Stage IV in the UMEC/VI 62.
5/25 µg group compared with placebo;
may skew the treatment effect in favour
of placebo. Lower proportion of current
smokers than comparable studies
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AE: adverse event; AUC: area under the curve; ATS: American Thoracic Society; BD: bronchodilator; bpm: beats per minute; CDLM:
capacity of daily living during the morning; COI: conflict of interest; COPD: chronic obstructive pulmonary disease; CR10:
category ratio 10; ECG: echocardiogram; ERS: European Respiratory Society; FEV1: forced expiratory volume in 1 second; FP:
fluticasone propionate; FPI-SF: functional performance inventory-short-form; FRC: functional residual capacity; FVC: forced vital
capacity; GOLD: Global Initiative for chronic obstructive pulmonary disease; H1: histamine 1; IC: inspiratory capacity; ICS:
inhaled corticosteroid; IgE: immunoglobulin E; IND: indacaterol; IRT: interactive voice response system; ITT: intent to treat; IVRS:
interactive voice response system; LABA: long-acting beta-adrenoceptor agonist; LAMA: long-acting muscarinic antagonist; LSM:
least squares mean; MACE: major adverse cardiovascular event; MCID: minimally clinically important difference; mITT: modified
intent-to-treat; mMRC: modified Medical Research Council; MRC: Medical Research Council; N: number; O2:oxygen; OCS: oral
corticosteroids; OLO: olodaterol; PDE4: phosphodiesterase 4; PK Cmax: pharmacokinetic maximum plasma concentration; prn:
pro re nata (as needed); QT:Q-T interval; RAMOS: registration andmedical ordering system; SABA: short-acting beta-adrenoceptor
agonist; SAE: serious adverse event; SaO2: oxygen saturation; SD: standard deviation; SGRQ: St George’s Respiratory Questionnaire;
SOBDA: shortness of breath with daily activities; SpO2: peripheral capillary oxygen saturation; SSRI: selective serotonin reuptake
inhibitor; TDI: transition dyspnoea index; TIO: tiotropium; tmax:time to maximum plasma concentration; UMEC: umeclidinium;
VI: vilanterol; W: Watt.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aalbers 2015 Wrong intervention (combination inhaler not used)
Asai 2013 Wrong comparator (different LABA used in control arm)
Berton 2009 Wrong intervention (LABA/LAMA not administered in combined inhaler)
Buhl 2011 INTENSITY Wrong intervention (LABA/LAMA combination not evaluated)
Buhl 2015 TONADO 2nd Round: Wrong comparator (no placebo)
D’Urzo 2014 AUGMENT 2nd ROUND: Wrong intervention - LAMA/LABA administered twice daily
Decramer 2014 2nd Round: Wrong comparator (no placebo)
Di Marco 2005 Duration of treatment < 3 weeks
Donohue 2013b 2nd ROUND: Wrong intervention - LAMA/LABA administered twice daily
Donohue 2016 Duration of treatment < 3 weeks
Donohue 2016b 2nd Round: Wrong comparator (no placebo)
EUCTR2007-003648-31 Duration of treatment < 3 weeks
EUCTR2007-004435-30 Wrong intervention (combination inhaler not used)
EUCTR2009-015901-38 Duration of treatment < 3 weeks
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Evdokimov 2015 2nd Round: Wrong comparator (no placebo)
Evdokimov 2015b 2nd Round: Wrong comparator (no placebo)
Ferguson 2015 Wrong comparator (dose of indacaterol in the control group was greater than that in combination arm)
Fogarty 2014 Duration of treatment < 3 weeks
Hanania 2016 2nd Round: Wrong comparator (no placebo)
Hoshino 2014 Wrong intervention (combination inhaler not used)
Ichinose 2016 No placebo group
Ichinose 2017 2nd Round: Wrong comparator (no placebo)
Imran 2015 Duration of treatment < 3 weeks
Jones 2010 Combined inhaler not used (LAMA plus LABA in individual inhalers)
Mahler 2015 2nd ROUND: Wrong intervention - LAMA/LABA administered twice daily
Maltais 2010 2nd Round: Wrong comparator (no placebo)
NCT00308191 2006 Wrong intervention (combination inhaler not used)
NCT00424528 2006 Wrong intervention (combination inhaler not used)
NCT00696020 2008 2nd Round: Wrong comparator (no placebo)
NCT00720499 2008 Wrong comparator (no placebo)
NCT00845728 2009 Wrong intervention (LABA/LAMA combination not evaluated)
NCT00846586 2009 Wrong intervention (combination inhaler not used)
NCT00877383 2009 Wrong intervention (combination inhaler not used)
NCT01040689 2010 Wrong intervention (LABA/LAMA combination not evaluated)
NCT01040728 2010 Wrong intervention (LABA/LAMA combination not evaluated)
NCT01049360 2009 Treatment duration < 3 weeks
NCT01437540 2011 2nd Round: Wrong comparator (no placebo)
NCT01476813 2012 Wrong intervention (LABA/LAMA combination not evaluated)
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NCT01491802 2012 2nd Round: Wrong comparator (no placebo)
NCT01529632 2012 Wrong comparator (both individual LAMA and LABA received)
NCT01536262 2012 2nd Round: Wrong comparator (no placebo)
NCT01551888 2012 Treatment duration < 3 weeks
NCT01574651 2012 Wrong comparator (Indaceterol or glycopyrronium (i.e. FDC evaluated in intervention arm) not eval-
uated in comparator arm)
NCT01682863 2012 Wrong comparator (indacaterol dose in control arm different than used in FDC in intervention arm)
NCT01697696 2012 Wrong intervention (LABA/LAMA combination not evaluated)
NCT01703845 2012 Wrong comparator (no LAMA or LABA alone, or placebo)
NCT01817764 2013 Wrong comparator (no single agent, or placebo)
NCT01985334 2014 Wrong comparator (individual LAMA or LABA could be used based on prior treatment)
NCT02030535 2014 Wrong study design (single-dose study)
NCT02059434 2013 Treatment duration < 3 weeks (single ascending-dose study)
NCT02196714 2014 Wrong patient population (healthy volunteers)
NCT02231177 2008 2nd Round: Wrong comparator (no placebo)
NCT02296138 2015 No placebo group
NCT02343458 2015 LAMA/LABA administered twice daily
NCT02429765 2015 LAMA/LABA administered twice daily
NCT02442206 2015 Treatment duration < 3 weeks
NCT02465567 2015 Wrong comparator (no single agent, or placebo)
NCT02487446 2015 Wrong comparator (no single agent, or placebo)
NCT02487498 2015 Wrong comparator (no single agent, or placebo)
NCT02579850 2015 Wrong comparator (no single agent, or placebo)
NCT02643082 2015 Treatment duration < 3 weeks
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NCT02796677 2016 LAMA/LABA administered twice daily
NCT02845752 2016 Treatment duration < 3 weeks
NCT02937584 2016 Wrong intervention (LABA/LAMA combination not evaluated)
NCT02988869 2016 No placebo group
NCT03022097 2017 LAMA/LABA administered twice daily
NCT03024346 2016 Duration of treatment < 3 weeks
NCT03034915 2017 No placebo group
Orevillo 2016 Duration of treatment < 3 weeks
Rabe 2015 2nd ROUND: Wrong intervention - LAMA/LABA administered twice daily
Reisner 2011 Duration of treatment < 3 weeks
Reisner 2013 Duration of treatment < 3 weeks
Reisner 2016 2nd ROUND: Wrong intervention - LAMA/LABA administered twice daily
Reisner 2017 Duration of treatment < 3 weeks
Reisner 2017b 2nd Round: Wrong comparator (no placebo)
Sadigov 2014 2nd Round: Wrong comparator (no placebo)
Salomon 2017 Wrong intervention (LABA/LAMA not administered in combined inhaler)
Setoguchi 2015 2nd Round: Wrong comparator (no placebo)
Singh 2014 2nd ROUND: Wrong intervention - LAMA/LABA administered twice daily
Sliwinski 2010 Wrong intervention (LABA/LAMA not administered in combined inhaler)
Tanaka 2015 2nd Round: Wrong comparator (no placebo)
Tashkin 2007 Wrong intervention (LABA/LAMA not administered in combined inhaler)
Tashkin 2016 Duration of treatment < 3 weeks
Ulubay 2005 2nd Round: Wrong comparator (no placebo)
Van de Maele 2010 Duration of treatment < 3 weeks
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Van Noord 2005 Wrong intervention (LABA/LAMA not administered in combined inhaler)
Van Noord 2010 Duration of treatment < 3 weeks
Velazquez-Uncal 2016 Wrong intervention (LABA/LAMA not evaluated)
Vincken 2013 Wrong intervention (LABA/LAMA not administered in combined inhaler)
Vogelmeier 2008 Wrong intervention (LABA/LAMA not administered in combined inhaler)
Vogelmeier 2013 Wrong comparator (LABA/LAMA vs LABA steroids)
Watz 2017 2nd ROUND: Wrong intervention - LAMA/LABA administered twice daily
Webb 2015 2nd Round: Wrong comparator (no placebo)
Wedzicha 2013 2nd Round: Wrong comparator (no placebo)
Yosuke 2014 2nd Round: Wrong comparator (no placebo)





Characteristics of studies awaiting assessment [ordered by study ID]
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NCT02233543 2014
Methods Study ID and dates performed: NCT02233543; Nov 2014 to June 2016; trial registry entry only (clinicaltrials.
gov); no data submitted
Study design: Randomised, placebo-controlled, cross-over trial.
Duration of study: 12 weeks (4 weeks per treatment, 2-week washout).
Study setting, location, number of centres: Not reported.
Key inclusion criteria: Aged ≥ 40 years; clinical diagnosis of COPD (according to GOLD guidelines, updated
2014) with a post-bronchodilator FEV1/FVC < 0.70; post-bronchodilator FEV1≥ 30% and < 60% of the predicted
normal value; resting daytime oxygen saturation levels measured by pulse oximetry of≤ 95% SpO2; smoking history
of at least 10 pack years (ten pack-years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20
years)
Key exclusion criteria: An exacerbation of COPD (treatment with oral or parenteral antibiotics and/or glucocorti-
costeroids and/or hospitalisation related to COPD) within 4 weeks prior to screening or during the run-in period;
diagnosed asthma; participants receiving regular long-term oxygen therapy; ongoing/planned rehabilitation during
the study period; three or more awakenings during the night leading to toilet visit or other reasons for exiting the
bed during the last week prior to the screening visit due to non-COPD reasons
Concomitant medications: Not reported.
Participants Note: cross-over study therefore participant data reported for whole cohort; no data posted.
N randomised: No data posted to trial registry site; no report available.
N analysed: No data posted to trial registry site; no report available.
Mean age (SD), years: No data posted to trial registry site; no report available.
Gender - male, n/N (%): No data posted to trial registry site; no report available.
Baseline lung function - post-bronchodilator % predicted FEV1: No data posted to trial registry site; no report
available.
Smoking status, current smoker, n/N (%): No data posted to trial registry site; no report available.
Interventions Intervention: Once-daily IND/GLY 85/43 µg.
Comparator: Once-daily placebo.
Outcomes Prespecified outcomes: Primary:Mean night-time blood oxygenation at 4 weeks.Secondary:Time during the night
spent below 90% in blood oxygen saturation at 4 weeks
Reported outcomes: No result posted.
Notes Funding for trial; notable author COIs: Study sponsored by Novartis Pharmaceuticals.
AE, adverse event; BD, bronchodilator; COI: conflict of interest; COPD: chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1 second; FVC, forced vital capacity; GLY: glycopyrrolate; GOLD: Global Initiative for Chronic Obstructive
Lung Disease; ICS: inhaled corticosteroid; IND: indacaterol; IRT, Interactive Response Technology; MCID, minimum clinically
important difference; SAE, serious adverse event; SD, standard deviation; SGRQ, St George’s Respiratory Questionaire; SpO2:
oxygen saturation; SSRI, selective serotonin reuptake inhibitor.
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D A T A A N D A N A L Y S E S
Comparison 1. LABA/LAMA versus placebo




participants Statistical method Effect size
1 All-cause mortality 18 8752 Odds Ratio (M-H, Fixed, 95% CI) 1.88 [0.81, 4.36]
1.1 IND/GLY 110/50 5 2020 Odds Ratio (M-H, Fixed, 95% CI) 2.53 [0.61, 10.49]
1.2 UMEC/VI 62.5/25 5 1921 Odds Ratio (M-H, Fixed, 95% CI) 3.12 [0.68, 14.36]
1.3 UMEC/VI 125/25 4 1401 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.83]
1.4 UMEC/VI 500/25 1 51 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 TIO/OLO 2.5/5 6 1670 Odds Ratio (M-H, Fixed, 95% CI) 2.53 [0.12, 53.43]
1.6 TIO/OLO 5/5 6 1689 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 SAEs 22 10536 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.88, 1.28]
2.1 IND/GLY 110/50 6 2830 Odds Ratio (M-H, Fixed, 95% CI) 1.16 [0.86, 1.56]
2.2 UMEC/VI 62.5/25 6 2317 Odds Ratio (M-H, Fixed, 95% CI) 1.29 [0.86, 1.93]
2.3 UMEC/VI 125/25 4 1403 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.46, 1.22]
2.4 UMEC/VI 500/25 1 51 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 TIO/OLO 2.5/5 6 1670 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.49, 1.68]
2.6 TIO/OLO 5/5 7 1840 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.55, 1.73]
2.7 ACM/FOR 200/6 1 141 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.02, 12.96]
2.8 ACM/FOR 200/12 1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.02, 13.07]
2.9 ACM/FOR 200/18 1 144 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.06, 22.41]
3 AECOPD 3 1127 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.36, 0.78]
3.1 UMEC/VI 62.5/25 2 786 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.37, 0.93]
3.2 UMEC/VI 125/25 1 290 Odds Ratio (M-H, Fixed, 95% CI) 0.37 [0.17, 0.78]
3.3 UMEC/VI 500/25 1 51 Odds Ratio (M-H, Fixed, 95% CI) 1.68 [0.08, 35.43]
4 Time to first AECOPD 2 1371 Hazard Ratio (Fixed, 95% CI) 0.44 [0.31, 0.63]
4.1 UMEC/VI 125/25 2 1371 Hazard Ratio (Fixed, 95% CI) 0.44 [0.31, 0.63]
5 Difference vs placebo in adjusted
SGRQ score (HRQoL)
8 4952 Mean Difference (Fixed, 95% CI) -4.08 [-4.80, -3.36]
5.1 IND/GLY 110/50 2 1370 Mean Difference (Fixed, 95% CI) -3.88 [-5.30, -2.45]
5.2 UMEC/VI 62.5/25 3 1425 Mean Difference (Fixed, 95% CI) -4.25 [-5.73, -2.77]
5.3 UMEC/VI 125/25 2 1000 Mean Difference (Fixed, 95% CI) -3.64 [-5.48, -1.80]
5.4 TIO/OLO 2.5/5 2 579 Mean Difference (Fixed, 95% CI) -3.89 [-5.60, -2.17]
5.5 TIO/OLO 5/5 2 578 Mean Difference (Fixed, 95% CI) -4.72 [-6.43, -3.01]
6 SGRQ responder analysis 7 4258 Odds Ratio (M-H, Fixed, 95% CI) 1.75 [1.54, 1.99]
6.1 IND/GLY 110/50 1 706 Odds Ratio (M-H, Fixed, 95% CI) 1.35 [0.98, 1.86]
6.2 TIO/OLO 2.5/5 2 579 Odds Ratio (M-H, Fixed, 95% CI) 1.87 [1.30, 2.70]
6.3 TIO/OLO 5/5 2 578 Odds Ratio (M-H, Fixed, 95% CI) 2.35 [1.63, 3.40]
6.4 UMEC/VI 62.5/25 3 1441 Odds Ratio (M-H, Fixed, 95% CI) 1.70 [1.37, 2.12]
6.5 UMEC/VI 125/25 2 954 Odds Ratio (M-H, Fixed, 95% CI) 1.78 [1.35, 2.34]
7 Difference vs placebo in adjusted
trough FEV1 at EOT
13 6598 Mean Difference (Fixed, 95% CI) 0.20 [0.19, 0.21]
7.1 IND/GLY 110/50 2 1018 Mean Difference (Fixed, 95% CI) 0.25 [0.22, 0.28]
7.2 UMEC/VI 62.5/25 6 2158 Mean Difference (Fixed, 95% CI) 0.18 [0.17, 0.20]
7.3 UMEC/VI 125/25 4 1304 Mean Difference (Fixed, 95% CI) 0.22 [0.20, 0.25]
7.4 TIO/OLO 2.5/5 3 845 Mean Difference (Fixed, 95% CI) 0.18 [0.15, 0.20]
7.5 TIO/OLO 5/5 3 859 Mean Difference (Fixed, 95% CI) 0.21 [0.18, 0.23]
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7.6 ACLID/FORM 200/6 1 137 Mean Difference (Fixed, 95% CI) 0.07 [-0.04, 0.18]
7.7 ACLID/FORM 200/12 1 137 Mean Difference (Fixed, 95% CI) 0.12 [0.01, 0.22]
7.8 ACLID/FORM 200/18 1 140 Mean Difference (Fixed, 95% CI) 0.08 [-0.04, 0.19]
8 Difference vs placebo in trough
FEV1 at EOT
5 2330 Mean Difference (Fixed, 95% CI) 0.18 [0.16, 0.20]
8.1 IND/GLY 110/50 3 1139 Mean Difference (Fixed, 95% CI) 0.20 [0.17, 0.22]
8.2 TIO/OLO 2.5/5 2 596 Mean Difference (Fixed, 95% CI) 0.16 [0.13, 0.19]
8.3 TIO/OLO 5/5 2 595 Mean Difference (Fixed, 95% CI) 0.16 [0.13, 0.20]
9 Difference vs placebo in trough
FEV1 - pooled adjusted and
EOT analyses
18 Mean Difference (Fixed, 95% CI) 0.20 [0.19, 0.20]
9.1 IND/GLY 110/50 5 Mean Difference (Fixed, 95% CI) 0.22 [0.21, 0.24]
9.2 UMEC/VI 125/25 4 Mean Difference (Fixed, 95% CI) 0.22 [0.20, 0.25]
9.3 UMEC/VI 62.5/25 6 Mean Difference (Fixed, 95% CI) 0.18 [0.17, 0.20]
9.4 TIO/OLO 2.5/5 5 Mean Difference (Fixed, 95% CI) 0.17 [0.15, 0.19]
9.5 TIO/OLO 5/5 5 Mean Difference (Fixed, 95% CI) 0.19 [0.17, 0.21]
9.6 ACLID/FORM 200/6 1 Mean Difference (Fixed, 95% CI) 0.07 [-0.04, 0.18]
9.7 ACLID/FORM 200/12 1 Mean Difference (Fixed, 95% CI) 0.12 [0.01, 0.22]
9.8 ACLID/FORM 200/18 1 Mean Difference (Fixed, 95% CI) 0.08 [-0.04, 0.19]
10 Difference vs placebo in
adjusted peak FEV1
7 4188 Mean Difference (Fixed, 95% CI) 0.31 [0.29, 0.32]
10.1 IND/GLY 110/50 2 1094 Mean Difference (Fixed, 95% CI) 0.35 [0.32, 0.38]
10.2 UMEC/VI 62.5/25 1 693 Mean Difference (Fixed, 95% CI) 0.22 [0.18, 0.27]
10.3 UMEC/VI 125/25 1 678 Mean Difference (Fixed, 95% CI) 0.28 [0.24, 0.32]
10.4 TIO/OLO 2.5/5 2 644 Mean Difference (Fixed, 95% CI) 0.29 [0.27, 0.32]
10.5 TIO/OLO 5/5 2 656 Mean Difference (Fixed, 95% CI) 0.33 [0.30, 0.35]
10.6 ACLID/FORM 200/6 1 140 Mean Difference (Fixed, 95% CI) 0.25 [0.13, 0.37]
10.7 ACLID/FORM 200/12 1 139 Mean Difference (Fixed, 95% CI) 0.31 [0.20, 0.43]
10.8 ACLID/FORM 200/18 1 144 Mean Difference (Fixed, 95% CI) 0.31 [0.19, 0.42]
11 AEs 17 8235 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.86, 1.04]
11.1 IND/GLY 110/50 6 2830 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.76, 1.07]
11.2 UMEC/VI 62.5/25 5 1921 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.88, 1.29]
11.3 UMEC/VI 125/25 4 1401 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.86, 1.34]
11.4 UMEC/VI 500/25 1 51 Odds Ratio (M-H, Fixed, 95% CI) 2.84 [0.32, 25.36]
11.5 TIO/OLO 2.5/5 4 1011 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.66, 1.11]
11.6 TIO/OLO 5/5 4 1021 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.60, 1.01]
Comparison 2. LABA/LAMA versus placebo < 6 months




participants Statistical method Effect size
1 All-cause mortality 16 7708 Odds Ratio (M-H, Fixed, 95% CI) 1.86 [0.75, 4.60]
1.1 IND/GLY 110/50 3 976 Odds Ratio (M-H, Fixed, 95% CI) 2.97 [0.47, 18.97]
1.2 UMEC/VI 62.5/25 5 1921 Odds Ratio (M-H, Fixed, 95% CI) 3.12 [0.68, 14.36]
1.3 UMEC/VI 125/25 4 1401 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.83]
1.4 UMEC/VI 500/25 1 51 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 TIO/OLO 2.5/5 6 1670 Odds Ratio (M-H, Fixed, 95% CI) 2.53 [0.12, 53.43]
1.6 TIO/OLO 5/5 6 1689 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 SAEs 19 8682 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.80, 1.29]
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2.1 IND/GLY 110/50 3 976 Odds Ratio (M-H, Fixed, 95% CI) 1.35 [0.54, 3.40]
2.2 UMEC/VI 62.5/25 6 2317 Odds Ratio (M-H, Fixed, 95% CI) 1.29 [0.86, 1.93]
2.3 UMEC/VI 125/25 4 1403 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.46, 1.22]
2.4 UMEC/VI 500/25 1 51 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 TIO/OLO 2.5/5 6 1670 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.49, 1.68]
2.6 TIO/OLO 5/5 7 1840 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.55, 1.73]
2.7 ACM/FOR 200/6 1 141 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.02, 12.96]
2.8 ACM/FOR 200/12 1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.02, 13.07]
2.9 ACM/FOR 200/18 1 144 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.06, 22.41]
3 AECOPD 3 1127 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.36, 0.78]
3.1 UMEC/VI 62.5/25 2 786 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.37, 0.93]
3.2 UMEC/VI 125/25 1 290 Odds Ratio (M-H, Fixed, 95% CI) 0.37 [0.17, 0.78]
3.3 UMEC/VI 500/25 1 51 Odds Ratio (M-H, Fixed, 95% CI) 1.68 [0.08, 35.43]
4 Time to first AECOPD 2 Hazard Ratio (Fixed, 95% CI) 0.44 [0.31, 0.63]
4.1 UMEC/VI 125/25 2 Hazard Ratio (Fixed, 95% CI) 0.44 [0.31, 0.63]
5 Difference vs placebo in adjusted
SGRQ score (HRQoL)
6 Mean Difference (Fixed, 95% CI) -4.15 [-4.99, -3.32]
5.1 UMEC/VI 62.5/25 3 Mean Difference (Fixed, 95% CI) -4.25 [-5.73, -2.77]
5.2 UMEC/VI 125/25 2 Mean Difference (Fixed, 95% CI) -3.64 [-5.48, -1.80]
5.3 TIO/OLO 2.5/5 2 Mean Difference (Fixed, 95% CI) -3.89 [-5.60, -2.17]
5.4 TIO/OLO 5/5 2 Mean Difference (Fixed, 95% CI) -4.72 [-6.43, -3.01]
6 SGRQ responder analysis 6 3552 Odds Ratio (M-H, Fixed, 95% CI) 1.84 [1.59, 2.12]
6.1 TIO/OLO 2.5/5 2 579 Odds Ratio (M-H, Fixed, 95% CI) 1.87 [1.30, 2.70]
6.2 TIO/OLO 5/5 2 578 Odds Ratio (M-H, Fixed, 95% CI) 2.35 [1.63, 3.40]
6.3 UMEC/VI 62.5/25 3 1441 Odds Ratio (M-H, Fixed, 95% CI) 1.70 [1.37, 2.12]
6.4 UMEC/VI 125/25 2 954 Odds Ratio (M-H, Fixed, 95% CI) 1.78 [1.35, 2.34]
Comparison 3. LABA/LAMA versus placebo ≥ 6 months




participants Statistical method Effect size
1 All-cause mortality 2 1044 Odds Ratio (M-H, Fixed, 95% CI) 2.03 [0.22, 18.35]
1.1 IND/GLY 110/50 2 1044 Odds Ratio (M-H, Fixed, 95% CI) 2.03 [0.22, 18.35]
2 SAEs 3 1854 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.83, 1.56]
2.1 IND/GLY 110/50 3 1854 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.83, 1.56]
3 Difference vs placebo in adjusted
SGRQ score (HRQoL)
2 Mean Difference (Fixed, 95% CI) -3.88 [-5.30, -2.45]
3.1 IND/GLY 110/50 2 Mean Difference (Fixed, 95% CI) -3.88 [-5.30, -2.45]
4 SGRQ responder analysis 1 706 Odds Ratio (M-H, Fixed, 95% CI) 1.35 [0.98, 1.86]
4.1 IND/GLY 110/50 1 706 Odds Ratio (M-H, Fixed, 95% CI) 1.35 [0.98, 1.86]
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Comparison 4. Sensitivity analysis - random-effects model




participants Statistical method Effect size
1 All-cause mortality 18 8752 Odds Ratio (M-H, Random, 95% CI) 2.02 [0.79, 5.17]
1.1 IND/GLY 110/50 5 2020 Odds Ratio (M-H, Random, 95% CI) 2.54 [0.61, 10.48]
1.2 TIO/OLO 2.5/5 6 1670 Odds Ratio (M-H, Random, 95% CI) 2.53 [0.12, 53.43]
1.3 TIO/OLO 5/5 6 1689 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 UMEC/VI 62.5/25 5 1921 Odds Ratio (M-H, Random, 95% CI) 2.92 [0.62, 13.79]
1.5 UMEC/VI 125/25 4 1401 Odds Ratio (M-H, Random, 95% CI) 0.14 [0.01, 2.83]
1.6 UMEC/VI 500/25 1 51 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 SAEs 22 10536 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.87, 1.27]
2.1 IND/GLY 110/50 6 2830 Odds Ratio (M-H, Random, 95% CI) 1.15 [0.85, 1.55]
2.2 TIO/OLO 2.5/5 6 1670 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.47, 1.68]
2.3 TIO/OLO 5/5 7 1840 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.53, 1.74]
2.4 UMEC/VI 62.5/25 6 2317 Odds Ratio (M-H, Random, 95% CI) 1.28 [0.85, 1.92]
2.5 UMEC/VI 125/25 4 1403 Odds Ratio (M-H, Random, 95% CI) 0.73 [0.41, 1.30]
2.6 UMEC/VI 500/25 1 51 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.7 ACM/FOR 200/6 1 141 Odds Ratio (M-H, Random, 95% CI) 0.51 [0.02, 12.96]
2.8 ACM/FOR 200/12 1 140 Odds Ratio (M-H, Random, 95% CI) 0.51 [0.02, 13.07]
2.9 ACM/FOR 200/18 1 144 Odds Ratio (M-H, Random, 95% CI) 1.11 [0.06, 22.41]
3 AECOPD 3 1127 Odds Ratio (M-H, Random, 95% CI) 0.52 [0.35, 0.78]
3.1 UMEC/VI 62.5/25 2 786 Odds Ratio (M-H, Random, 95% CI) 0.58 [0.36, 0.93]
3.2 UMEC/VI 125/25 1 290 Odds Ratio (M-H, Random, 95% CI) 0.37 [0.17, 0.78]
3.3 UMEC/VI 500/25 1 51 Odds Ratio (M-H, Random, 95% CI) 1.68 [0.08, 35.43]
4 Time to first AECOPD 2 Hazard Ratio (Random, 95% CI) 0.44 [0.31, 0.63]
4.1 UMEC/VI 125/25 2 Hazard Ratio (Random, 95% CI) 0.44 [0.31, 0.63]
5 Difference vs placebo in adjusted
SGRQ score (HRQoL)
8 Mean Difference (Random, 95% CI) -4.08 [-4.80, -3.36]
5.1 IND/GLY 110/50 2 Mean Difference (Random, 95% CI) -3.87 [-5.53, -2.22]
5.2 UMEC/VI 125/25 2 Mean Difference (Random, 95% CI) -3.64 [-5.48, -1.80]
5.3 UMEC/VI 62.5/25 3 Mean Difference (Random, 95% CI) -4.18 [-5.92, -2.44]
5.4 TIO/OLO 2.5/5 2 Mean Difference (Random, 95% CI) -3.89 [-5.60, -2.17]
5.5 TIO/OLO 5/5 2 Mean Difference (Random, 95% CI) -4.72 [-6.43, -3.01]
6 SGRQ responder analysis 7 4258 Odds Ratio (M-H, Random, 95% CI) 1.74 [1.53, 1.99]
6.1 IND/GLY 110/50 1 706 Odds Ratio (M-H, Random, 95% CI) 1.35 [0.98, 1.86]
6.2 TIO/OLO 2.5/5 2 579 Odds Ratio (M-H, Random, 95% CI) 1.87 [1.30, 2.70]
6.3 TIO/OLO 5/5 2 578 Odds Ratio (M-H, Random, 95% CI) 2.35 [1.63, 3.40]
6.4 UMEC/VI 62.5/25 3 1441 Odds Ratio (M-H, Random, 95% CI) 1.70 [1.37, 2.12]
6.5 UMEC/VI 125/25 2 954 Odds Ratio (M-H, Random, 95% CI) 1.78 [1.35, 2.34]
7 Difference vs placebo in adjusted
trough FEV1 at EOT
13 Mean Difference (Random, 95% CI) 0.20 [0.18, 0.21]
7.1 IND/GLY 110/50 2 Mean Difference (Random, 95% CI) 0.25 [0.20, 0.30]
7.2 UMEC/VI 125/25 4 Mean Difference (Random, 95% CI) 0.22 [0.18, 0.26]
7.3 UMEC/VI 62.5/25 6 Mean Difference (Random, 95% CI) 0.18 [0.15, 0.22]
7.4 TIO/OLO 2.5/5 3 Mean Difference (Random, 95% CI) 0.18 [0.15, 0.20]
7.5 TIO/OLO 5/5 3 Mean Difference (Random, 95% CI) 0.21 [0.18, 0.23]
7.6 ACLID/FORM 200/6 1 Mean Difference (Random, 95% CI) 0.07 [-0.04, 0.18]
7.7 ACLID/FORM 200/12 1 Mean Difference (Random, 95% CI) 0.12 [0.01, 0.22]
7.8 ACLID/FORM 200/18 1 Mean Difference (Random, 95% CI) 0.08 [-0.04, 0.19]
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8 Difference vs placebo in trough
FEV1 at EOT
5 Mean Difference (Random, 95% CI) 0.18 [0.16, 0.20]
8.1 IND/GLY 110/50 3 Mean Difference (Random, 95% CI) 0.20 [0.17, 0.22]
8.2 TIO/OLO 2.5/5 2 Mean Difference (Random, 95% CI) 0.16 [0.13, 0.19]
8.3 TIO/OLO 5/5 2 Mean Difference (Random, 95% CI) 0.16 [0.13, 0.20]
9 Difference vs placebo in adjusted
peak FEV1
7 Mean Difference (Random, 95% CI) 0.30 [0.28, 0.33]
9.1 IND/GLY 110/50 2 Mean Difference (Random, 95% CI) 0.35 [0.31, 0.39]
9.2 UMEC/VI 125/25 1 Mean Difference (Random, 95% CI) 0.28 [0.24, 0.32]
9.3 UMEC/VI 62.5/25 1 Mean Difference (Random, 95% CI) 0.22 [0.18, 0.27]
9.4 TIO/OLO 2.5/5 2 Mean Difference (Random, 95% CI) 0.29 [0.27, 0.32]
9.5 TIO/OLO 5/5 2 Mean Difference (Random, 95% CI) 0.33 [0.30, 0.35]
9.6 ACLID/FORM 200/6 1 Mean Difference (Random, 95% CI) 0.25 [0.13, 0.37]
9.7 ACLID/FORM 200/12 1 Mean Difference (Random, 95% CI) 0.31 [0.20, 0.43]
9.8 ACLID/FORM 200/18 1 Mean Difference (Random, 95% CI) 0.31 [0.19, 0.42]
10 AEs 17 8235 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.86, 1.04]
10.1 IND/GLY 110/50 6 2830 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.76, 1.07]
10.2 TIO/OLO 2.5/5 4 1011 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.65, 1.11]
10.3 TIO/OLO 5/5 4 1021 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.60, 1.01]
10.4 UMEC/VI 62.5/25 5 1921 Odds Ratio (M-H, Random, 95% CI) 1.07 [0.88, 1.29]
10.5 UMEC/VI 125/25 4 1401 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.86, 1.34]
10.6 UMEC/VI 500/25 1 51 Odds Ratio (M-H, Random, 95% CI) 2.84 [0.32, 25.36]
11 Difference vs placebo in trough
FEV1 - pooled adjusted and
EOT analyses
18 Mean Difference (Random, 95% CI) 0.20 [0.19, 0.21]
11.1 IND/GLY 110/50 5 Mean Difference (Random, 95% CI) 0.22 [0.19, 0.26]
11.2 UMEC/VI 125/25 4 Mean Difference (Random, 95% CI) 0.22 [0.18, 0.26]
11.3 UMEC/VI 62.5/25 6 Mean Difference (Random, 95% CI) 0.18 [0.15, 0.22]
11.4 TIO/OLO 2.5/5 5 Mean Difference (Random, 95% CI) 0.18 [0.15, 0.20]
11.5 TIO/OLO 5/5 5 Mean Difference (Random, 95% CI) 0.20 [0.18, 0.21]
11.6 ACLID/FORM 200/6 1 Mean Difference (Random, 95% CI) 0.07 [-0.04, 0.18]
11.7 ACLID/FORM 200/12 1 Mean Difference (Random, 95% CI) 0.12 [0.01, 0.22]
11.8 ACLID/FORM 200/18 1 Mean Difference (Random, 95% CI) 0.08 [-0.04, 0.19]
Comparison 5. Sensitivity analysis - RoB




participants Statistical method Effect size
1 All-cause mortality 14 7287 Odds Ratio (M-H, Fixed, 95% CI) 1.65 [0.60, 4.50]
1.1 IND/GLY 110/50 4 1682 Odds Ratio (M-H, Fixed, 95% CI) 2.97 [0.47, 18.97]
1.2 TIO/OLO 2.5/5 6 1670 Odds Ratio (M-H, Fixed, 95% CI) 2.53 [0.12, 53.43]
1.3 TIO/OLO 5/5 6 1689 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 UMEC/VI 62.5/25 3 1135 Odds Ratio (M-H, Fixed, 95% CI) 3.22 [0.38, 27.52]
1.5 UMEC/VI 125/25 3 1111 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.83]
2 SAEs 17 8448 Odds Ratio (M-H, Fixed, 95% CI) 1.09 [0.86, 1.40]
2.1 IND/GLY 110/50 5 2020 Odds Ratio (M-H, Fixed, 95% CI) 1.23 [0.79, 1.89]
2.2 TIO/OLO 2.5/5 6 1670 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.49, 1.68]
2.3 TIO/OLO 5/5 6 1689 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.54, 1.91]
2.4 UMEC/VI 62.5/25 4 1531 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [0.75, 2.40]
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2.5 UMEC/VI 125/25 3 1113 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.55, 1.66]
2.6 ACM/FOR 200/6 1 141 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.02, 12.96]
2.7 ACM/FOR 200/12 1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.02, 13.07]
2.8 ACM/FOR 200/18 1 144 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.06, 22.41]
3 Time to first AECOPD 2 Hazard Ratio (Fixed, 95% CI) 0.44 [0.31, 0.63]
3.1 UMEC/VI 125/25 2 Hazard Ratio (Fixed, 95% CI) 0.44 [0.31, 0.63]
4 Difference vs placebo in adjusted
SGRQ score (HRQoL)
5 Mean Difference (Fixed, 95% CI) -4.12 [-4.99, -3.24]
4.1 IND/GLY 110/50 1 Mean Difference (Fixed, 95% CI) -3.01 [-5.05, -0.97]
4.2 UMEC/VI 125/25 1 Mean Difference (Fixed, 95% CI) -3.60 [-5.76, -1.44]
4.3 UMEC/VI 62.5/25 1 Mean Difference (Fixed, 95% CI) -5.51 [-7.88, -3.14]
4.4 TIO/OLO 2.5/5 2 Mean Difference (Fixed, 95% CI) -3.89 [-5.60, -2.17]
4.5 TIO/OLO 5/5 2 Mean Difference (Fixed, 95% CI) -4.72 [-6.43, -3.01]
5 SGRQ responder analysis 5 3234 Odds Ratio (M-H, Fixed, 95% CI) 1.81 [1.56, 2.10]
5.1 IND/GLY 110/50 1 706 Odds Ratio (M-H, Fixed, 95% CI) 1.35 [0.98, 1.86]
5.2 TIO/OLO 2.5/5 2 579 Odds Ratio (M-H, Fixed, 95% CI) 1.87 [1.30, 2.70]
5.3 TIO/OLO 5/5 2 578 Odds Ratio (M-H, Fixed, 95% CI) 2.35 [1.63, 3.40]
5.4 UMEC/VI 62.5/25 1 693 Odds Ratio (M-H, Fixed, 95% CI) 1.88 [1.37, 2.59]
5.5 UMEC/VI 125/25 1 678 Odds Ratio (M-H, Fixed, 95% CI) 1.83 [1.32, 2.54]
6 Difference vs placebo in adjusted
trough FEV1 at EOT
10 Mean Difference (Fixed, 95% CI) 0.20 [0.19, 0.22]
6.1 IND/GLY 110/50 1 Mean Difference (Fixed, 95% CI) 0.28 [0.24, 0.32]
6.2 UMEC/VI 125/25 3 Mean Difference (Fixed, 95% CI) 0.22 [0.20, 0.25]
6.3 UMEC/VI 62.5/25 4 Mean Difference (Fixed, 95% CI) 0.20 [0.18, 0.22]
6.4 TIO/OLO 2.5/5 3 Mean Difference (Fixed, 95% CI) 0.18 [0.15, 0.20]
6.5 TIO/OLO 5/5 3 Mean Difference (Fixed, 95% CI) 0.21 [0.18, 0.23]
6.6 ACLID/FORM 200/6 1 Mean Difference (Fixed, 95% CI) 0.07 [-0.04, 0.18]
6.7 ACLID/FORM 200/12 1 Mean Difference (Fixed, 95% CI) 0.12 [0.01, 0.22]
6.8 ACLID/FORM 200/18 1 Mean Difference (Fixed, 95% CI) 0.08 [-0.04, 0.19]
7 Difference vs placebo in trough
FEV1 at EOT
4 Mean Difference (Fixed, 95% CI) 0.18 [0.16, 0.20]
7.1 IND/GLY 110/50 2 Mean Difference (Fixed, 95% CI) 0.2 [0.17, 0.23]
7.2 TIO/OLO 2.5/5 2 Mean Difference (Fixed, 95% CI) 0.16 [0.13, 0.19]
7.3 TIO/OLO 5/5 2 Mean Difference (Fixed, 95% CI) 0.16 [0.13, 0.20]
8 Difference vs placebo in adjusted
peak FEV1
7 Mean Difference (Fixed, 95% CI) 0.31 [0.29, 0.32]
8.1 IND/GLY 110/50 2 Mean Difference (Fixed, 95% CI) 0.35 [0.32, 0.38]
8.2 UMEC/VI 125/25 1 Mean Difference (Fixed, 95% CI) 0.28 [0.24, 0.32]
8.3 UMEC/VI 62.5/25 1 Mean Difference (Fixed, 95% CI) 0.22 [0.18, 0.27]
8.4 TIO/OLO 2.5/5 2 Mean Difference (Fixed, 95% CI) 0.29 [0.27, 0.32]
8.5 TIO/OLO 5/5 2 Mean Difference (Fixed, 95% CI) 0.33 [0.30, 0.35]
8.6 ACLID/FORM 200/6 1 Mean Difference (Fixed, 95% CI) 0.25 [0.13, 0.37]
8.7 ACLID/FORM 200/12 1 Mean Difference (Fixed, 95% CI) 0.31 [0.20, 0.43]
8.8 ACLID/FORM 200/18 1 Mean Difference (Fixed, 95% CI) 0.31 [0.19, 0.42]
9 AEs 11 5579 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.86, 1.08]
9.1 IND/GLY 110/50 3 1301 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.70, 1.19]
9.2 TIO/OLO 2.5/5 4 1011 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.66, 1.11]
9.3 TIO/OLO 5/5 4 1021 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.60, 1.01]
9.4 UMEC/VI 62.5/25 3 1135 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.89, 1.46]
9.5 UMEC/VI 125/25 3 1111 Odds Ratio (M-H, Fixed, 95% CI) 1.15 [0.90, 1.48]
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